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Abstract
Melanosomes are subcellular organelles specialized for the synthesis and storage of melanin pigments.
Within epidermal and ocular pigment cells, melanosomes are generated from endosomal precursors in
discrete stages. Early stages are characterized by the accumulation of premelanosome protein (PMEL)
and its assembly into nontoxic amyloid fibrils, while later stages are characterized by the arrival of
proteins important for the production of pigment. In this thesis, I will discuss two important findings
relevant to melanosome biology.
The first finding addresses the molecular mechanisms that regulate the transformation of PMEL from an
integral membrane protein to fibrillar structures with properties of amyloid. These data show that native
disulfide-bonded PMEL dimers prevent premature fibril formation early in the secretory pathway but must
be resolved prior to the assembly of functional amyloid fibrils in early stage melanosomes. Failure to
resolve the dimeric intermediates – as occurs with mutagenesis of a PMEL regulatory domain –
decreases amyloid production in a heterologous expression system. Since the oligomerization of amyloid
precursors is hardly unique, detailed characterization of the different intermediates formed by functional
versus pathological amyloid proteins may bring us one step closer to understanding the mechanisms of
neurodegenerative amyloid disease.
The second finding addresses the localization and potential function of SLC45A2, a proton-dependent
sucrose transporter encoded by the gene that is mutated in the hypopigmentary disorder oculocutaneous
albinism type 4 (OCA4). While melanocytes derived from patients and mouse models of OCA4 are known
to contain hypopigmented melanosomes, it is unclear why mutations in SLC45A2 lead to decreased
pigment production. Our data show that SLC45A2 localizes to and functions from distinct punctate
structures on/near stage III and IV melanosomes. Mislocalization of SLC45A2 leads to hypopigmentation
suggesting that the transporter must be present on melanosomal structures to function. Preliminary data
also suggest that SLC45A2-deficient melanocytes harbor melanosomes that are hypopigmented but
normally shaped and that SLC45A2 function can be bypassed by overexpression of a different
melanosomal transporter, OCA2. Along with other preliminary data, these results suggest that SLC45A2
likely maintains a neutral pH within maturing melanosomes to ensure sustained melanin deposition.
Together, these two studies provide insight into the molecular mechanisms that regulate nontoxic
amyloid and melanin production within healthy melanocytes.
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ABSTRACT

REGULATION OF FUNCTIONAL AMYLOID FORMATION AND PIGMENTATION
DURING MELANOSOME BIOGENESIS

Tina Ho
Michael S. Marks

Melanosomes are subcellular organelles specialized for the synthesis and storage of
melanin pigments. Within epidermal and ocular pigment cells, melanosomes are
generated from endosomal precursors in discrete stages. Early stages are characterized by
the accumulation of premelanosome protein (PMEL) and its assembly into nontoxic
amyloid fibrils, while later stages are characterized by the arrival of proteins important
for the production of pigment. In this thesis, I will discuss two important findings
relevant to melanosome biology.
The first finding addresses the molecular mechanisms that regulate the transformation of
PMEL from an integral membrane protein to fibrillar structures with properties of
amyloid. These data show that native disulfide-bonded PMEL dimers prevent premature
fibril formation early in the secretory pathway but must be resolved prior to the assembly
of functional amyloid fibrils in early stage melanosomes. Failure to resolve the dimeric
intermediates – as occurs with mutagenesis of a PMEL regulatory domain – decreases
amyloid production in a heterologous expression system. Since the oligomerization of
ii

	
  

amyloid precursors is hardly unique, detailed characterization of the different
intermediates formed by functional versus pathological amyloid proteins may bring us
one step closer to understanding the mechanisms of neurodegenerative amyloid disease.
The second finding addresses the localization and potential function of SLC45A2, a
proton-dependent sucrose transporter encoded by the gene that is mutated in the
hypopigmentary disorder oculocutaneous albinism type 4 (OCA4). While melanocytes
derived from patients and mouse models of OCA4 are known to contain hypopigmented
melanosomes, it is unclear why mutations in SLC45A2 lead to decreased pigment
production. Our data show that SLC45A2 localizes to and functions from distinct
punctate structures on/near stage III and IV melanosomes. Mislocalization of SLC45A2
leads to hypopigmentation suggesting that the transporter must be present on
melanosomal structures to function. Preliminary data also suggest that SLC45A2deficient melanocytes harbor melanosomes that are hypopigmented but normally shaped
and that SLC45A2 function can be bypassed by overexpression of a different
melanosomal transporter, OCA2. Along with other preliminary data, these results suggest
that SLC45A2 likely maintains a neutral pH within maturing melanosomes to ensure
sustained melanin deposition.
Together, these two studies provide insight into the molecular mechanisms that regulate
nontoxic amyloid and melanin production within healthy melanocytes.
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CHAPTER 1
Introduction: Functional Amyloid and Melanosome Biogenesis
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1.1 Introduction
Pigmentation has a variety of purposes in metazoans including mate selection,
camouflage, and communication (1). In humans and some other mammals, melanin is
primarily important for protection from UV damage and for proper development of the
visual system. Produced in specialized organelles known as melanosomes that are present
within pigment cells of the skin and eye, melanins are polymers composed of a
heterogenous mixture of redox-active compounds derived initially from the amino acid
tyrosine (2). Eumelanins, which are composed of indole products of tyrosine
hydroxylation and oxidation, serve as sinks for reactive oxygen species and thus protect
the skin and eyes from oxidative damage (2). Pheomelanin polymers result from
cysteinylation of tyrosine and are thought to be more pro-oxidative, correlating with
higher risk of skin cancers (2).
The melanosomes that harbor primarily eumelanins are specialized, membrane-bound
structures that are generated in skin and choroidal melanocytes and in the retinal, iris, and
ciliary body pigment epithelia of the eye. They are among the best characterized of a
series of cell type-specific “lysosome-related organelles” (LROs) that coexist with
lysosomes in their respective cell types (3). A challenge for pigment cells and other LROcontaining cell types is the ability to generate LROs during their development; in retinal
pigment epithelial cells, melanosomes are generated only during a short period of
prenatal development, but in other mammalian pigment cell types, they are generated
constantly. Proteins that underlie melanosome structure and that contribute to melanin
formation must be synthesized by the cell, processed through the classical secretory
2

	
  

pathway, and then diverted to newly forming melanosomes. How this occurs is just
beginning to be understood (4).
Eumelanosomes are particularly unusual in having a cylindrical shape and an
intralumenal fibrillar scaffold upon which melanins deposit as the melanosome matures
(5). This fibrillar scaffold develops prior to the onset of melanogenesis and is comprised
largely – if not entirely – of the functional amyloid protein PMEL (also known as
Pmel17, Silver, gp100 and ME20) (6). As discussed below, the amyloid fold is more
typically thought of in the context of disease, such as in Alzheimer or Parkinson disease,
but PMEL production in pigment cells is non-toxic.
The production of nontoxic amyloids and how this process differs from that of
pathological amyloid proteins is not known. We hypothesize that the formation of
nontoxic amyloid requires highly coordinated and robust mechanisms of regulation that
either do not exist or malfunction in amyloid disease. Therefore, in the first half of this
thesis, we examine one mechanism of regulation in which PMEL – a model functional
amyloid protein of the endomembrane system – forms dimers that maintain the protein in
a non-amyloid conformation as it traffics en route to early stage melanosomes.
Once fibrillar melanosome precursors are generated, they undergo a process of
maturation in which the enzymes and transporters that contribute to melanin synthesis are
delivered and activated. The key enzyme in the synthesis of all melanins is tyrosinase
(TYR), which catalyzes the limiting steps of tyrosine hydroxylation to L-DOPA and
oxidation of L-DOPA to DOPAquinone (2). Importantly, however, TYR is inactive at
acidic pH (7). This belies the fact that PMEL amyloid formation requires low pH, at least
3

	
  

initially to activate the proteolytic enzymes involved in PMEL maturation ((8); see
below). Thus, the internal environment of melanosomes must be modified for efficient
melanin biosynthesis to occur. This involves both a rise in pH (9) and changes to the
divalent cation composition (10-12). This is accomplished by the delivery of
transmembrane transporters specifically to the melanosome during maturation. For
example, delivery of the copper transporter ATP7A facilitates loading of copper into the
TYR active site (10), and delivery of the chloride channel, OCA2, facilitates pH
neutralization (13,14). Mutations in the genes encoding these transporters result in
hypopigmentation in animal models and oculocutaneous albinism (OCA) in humans.
Other transporters also likely function to maintain the proper intralumenal environment
within melanosomes. In the second half of this thesis, I investigate the molecular basis of
OCA type 4 (OCA4). This disorder is caused by mutations in SLC45A2 (15); however,
the role of SLC45A2 in melanosome biology is not well understood. I preliminarily
define the localization of SLC45A2 and present preliminary data to suggest that the
protein contributes to maintaining the neutral pH of late-stage melanosomes.

1.2 Amyloid
Associated with pathological conditions since the time of Virchow, the study of amyloid
today is still virtually synonymous with that of disease. The formation of amyloid has
been linked to both systemic amyloid diseases in which the deposition of amyloid
disrupts tissue architecture and stiffens affected organs as well as neurodegenerative
diseases in which the mechanism of disease is less well understood. However, not all
4

	
  

amyloid proteins are associated with pathology. Functional amyloid proteins such as curli
(16), RIP1/RIP3 (17), and PMEL (18) form nontoxic amyloid fibrils that actually
contribute to the well-being of the organism and do not participate in disease processes
under normal physiological conditions. By studying and comparing the formation of
functional amyloid with that of pathological amyloid, we hope to gain insight into the
molecular basis of Alzheimer, Parkinson, and other neurodegenerative amyloid diseases.
All amyloid proteins are defined by their ability to polymerize into cross-β-sheet fibrils
that are insoluble, resistant to protease degradation, and readily apparent by electron
microscopy (19). Most also bind traditional amyloid dyes such as Congo red and
thioflavin T. They are typically thought to be produced via a nucleated assembly
mechanism in which soluble monomers associate to form a stable nucleus during the lag
phase of fibril formation (Figure 1.1; (20)). This thermodynamically unfavorable process
either requires unstructured proteins to adopt a specific conformation or folded proteins
to partially unfold and adopt a new conformation. Once sufficient nuclei have formed,
however, soluble monomers are rapidly incorporated into the ends of growing fibrils
during the elongation phase of fibril formation.
The nucleated self-assembly process creates a diverse array of intermediates as well as a
heterogeneous final product. The intermediates are often crudely categorized as soluble
oligomers (such as dimers and trimers), nonfibrillar aggregates of higher molecular
weight, and protofibrils (21). The inherently metastable nature of these pre-amyloid
species makes it difficult for biophysicists to study their structure by traditional methods
such as X-ray crystallography or NMR and even harder for cell biologists to generalize
5

	
  

Figure 1.1

Nucleated assembly of amyloid fibrils. The kinetics of amyloid fibril formation are
consistent with a nucleation dependent mechanism in which the thermodynamically
unfavorable process of nucleus formation occurs during a lag phase but grow rapidly
during the elongation phase (black line). However, the lag phase is significantly
shortened if the process is seeded with preformed fibrils (red line). Adapted from: A
Diversity of Assembly Mechanisms of a Generic Amyloid Fold (20).
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about the effect of these species on cell health. Attempts have been made to isolate
relatively homogenous preparations of stable intermediates, however, and comparison of
the stable intermediates formed by functional versus pathological amyloid proteins might
one day be helpful in determining whether oligomers are responsible for the toxicity
associated with pathological amyloid formation and, if so, which particular intermediates
are to blame.

1.2.1 Aβ and Alzheimer Disease
Amyloid precursor protein (APP) is linked to Alzheimer’s disease (AD) since mutations
in APP result in familial forms of AD (22). In patients with AD, APP is cleaved first by
β-secretase and then by γ-secretase to form Aβ peptides. These peptides can be 39-42
amino acids in length; however, the most amyloidogenic is Aβ42. Aβ42 is the major
component of the amyloid plaques that accumulate in AD brains (23,24) and forms
highly insoluble amyloid fibrils more rapidly in vitro (25,26). Mutations in presenilin-1,
the catalytic subunit of the γ-secretase complex, can also increase the Aβ42:Aβ40 ratio
and cause familial AD (27).
Aβ plaques are a defining feature of AD; however, it remains controversial whether these
plaques constitute the pathogenic species of AD or whether pre-amyloid intermediates of
fibril formation are responsible for the neuronal loss and neurocognitive decline observed
in patients with AD. It is known that plaque burden correlates poorly with clinical
severity while levels of soluble non-fibrillar Aβ are a much better indicator of both
synaptic loss and disease progression (28,29). It has also been shown that Aβ dimers
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isolated from human brain tissue by size exclusion chromatography disrupted synaptic
function in rat brain slices – an effect that could be blocked by the addition of antibodies
to Aβ (30). Soluble AD brain lysate also impaired memory formation in live rats, while
the same lysate immunodepleted for Aβ did not suggesting that soluble Aβ intermediates
disrupt normal brain function in vivo.
These experiments raise many more questions than they answer, but the one we are most
interested in is what makes the brain-derived Aβ dimers in this experiment so toxic.
Moreover, how might functional amyloid proteins avoid such toxicity?

1.2.2 α-Synuclein and Parkinson Disease
Parkinson disease (PD) is genetically linked to α-synuclein since mutations in the protein
cause familial PD (31). α-Synuclein fibrils are the principal component of Lewy bodies,
the defining pathological feature of PD (32). Here too, oligomers emerged as a way to
explain the poor correlation between Lewy pathology and clinical features of PD. Lewy
bodies are observed in 12% of asymptomatic individuals on autopsy (33), and many
patients with familial forms of PD show no evidence of Lewy pathology postmortem
(34). Additionally, in a rat model system, variants of α-synuclein that were more prone to
form oligomers than fibrils led to greater dopaminergic loss than mutants that were more
prone to form fibrils than oligomers (35).
However, not all oligomers of α-synuclein appear to be toxic. The most interesting debate
in the field currently centers on the existence of native α-synuclein tetramers. Isolated
from cells in culture, mouse brain tissue, and red blood cells under non-denaturing
8

	
  

conditions or from E. coli using n-octylglucoside detergent, these tetramers exhibit αhelical structure and are resistant to amyloid formation (36,37). Physiological tetramers
of α-synuclein previously escaped detection because harsh conditions are often used to
purify recombinant α-synuclein based on studies characterizing α-synuclein as a natively
unfolded, intrinsically disordered protein (38). In addition, the α-helical structure of αsynuclein is stabilized by N-terminal acetylation, a post-translational modification found
in vivo but not in recombinant bacterially produced protein (at least not without coexpression of the fission yeast N-terminal acetylation B complex) (36,39,40). Together,
these data suggest that α-synuclein oligomerization may inhibit pathological amyloid
formation in vivo. They also demonstrate that in vitro studies performed using
recombinant protein should be interpreted with caution.

1.2.3 Functional amyloid
Functional amyloid proteins are a group of proteins that have all the biochemical and
biophysical properties of amyloid but are actually beneficial to the cells and organisms
that produce them (41). They have been observed in a wide variety of species ranging
from bacteria to humans and include extracellular amyloid proteins important in biofilm
formation (Figure 1.2A; (16)) as well as intracellular amyloid proteins that function in
learning and memory (42), innate immunity (17), and pigmentation (Figure 1.2C; (18)).
In order to be evolutionarily beneficial, however, these proteins must form amyloid
without destroying their hosts. How does the assembly of functional amyloid occur

9

	
  
Figure 1.2

Examples of amyloid. Amyloid fibrils can form extracellularly (A, B) or intracellularly
(C, D) and be functional (A, C) or pathological (B, D). Adapted from: Nanomechanics of
functional and pathological amyloid materials (50).
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without inducing any of the toxic effects associated with the deposition of pathological
amyloid proteins such as Aβ (Figure 1.2B) or α-synuclein (Figure 1.2D)?
An especially well-studied example of functional amyloid formation is that of curli fiber
production. The two curli operons csgBAC and csgDEFG encode seven proteins, all of
which are important for biofilm formation in E. coli. The primary component of curli
fibers, CsgA, has five imperfect repeats that are predicted to form the amyloid core (43).
CsgB is a minor subunit that both nucleates CsgA fibril formation (44) and cooperates
with CsgF to anchor growing fibers to the bacterial outer membrane (45). CsgC is a very
recently identified protein chaperone that prevents premature amyloid formation in the
bacterial periplasm; incredibly, CsgC can inhibit not only CsgA amyloid formation at a
1:500 molar ratio but also α-synuclein fibril formation at a 1:10 molar ratio (46). CsgD is
a transcription factor that activates the csgBAC operon (47). CsgG oligomerizes to form a
channel in the outer membrane necessary for CsgA and CsgB to pass from the periplasm
into the extracellular space (48,49), while the specificity factor CsgE binds to CsgG and
caps the periplasmic side of the channel (49). Together, these seven proteins illustrate the
complex regulation involved in functional amyloid formation – even in a prokaryote.
Several functional amyloid proteins have also been identified in yeast. The majority of
these are prions, or proteins that confer heritable and infectious traits to the yeast in
which they are present. They include Ure2p, which interferes with the ability of yeast to
adapt to nitrogen-rich environments (51,52), Sup35p, which regulates stop codon
readthrough (53,54), and Rnq1p, which helps other prion proteins adopt their amyloid
state (55). Remarkably, yeast can remodel both pre-amyloid oligomers and mature
11

	
  

amyloid fibrils using Hsp104, a chaperone with robust disaggregation activity. Using
ATP as an energy source, Hsp104 functions in concert with Hsp40 and Hsp70 chaperones
to solubilize and recover enzymatically active monomers from misfolded aggregates (56).
Cytoplasmic polyadenylation element-binding proteins (CPEBs) regulate protein
synthesis at the neuronal synapse, and isoforms in the sea snail Aplysia (ApCPEB) as
well as in Drosophila (Orb2) have been shown to play a role in the formation of longterm memories (42,57). With bacteria and yeast, structural studies are performed directly
on the amyloid proteins of interest. In higher organisms, however, detailed biophysical
characterizations are often done on recombinant protein with maybe one or two studies
performed in vivo to support the findings in vitro. This is true for ApCPEB and Orb2.
Recombinant ApCPEB forms fibrils visible by electron microscopy that bind Thioflavin
T and have a cross-β sheet X-ray diffraction pattern (57,58). Cells expressing an HAtagged variant of ApCPEB also stained with the amyloid dye Thioflavin S; however,
endogenous ApCPEB did not. Even fewer structural studies have been performed on the
Drosophila isoforms Orb2A and Orb2B, though recombinant versions of these proteins
do assemble into fibrils by electron microscopy (42).
Detailed structural studies were performed, however, on both light and heavy secretory
granules purified from rat pituitary (59). These experiments suggested that at least some
of the peptide hormones that form fibrils in vitro are indeed stored as amyloid in vivo as
the granules exhibited Congo Red birefringence, bound Thioflavin T, and had a cross-β
sheet X-ray fiber diffraction pattern. Of note, these functional amyloid fibrils
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depolymerized and released active monomers when dialyzed in Tris buffers of pH 6.0 or
pH 7.4. Some were also moderately toxic when applied to a neuronal cell line.
The diversity of functional amyloid suggests that there may be many ways to generate
amyloid without causing damage to cells and/or surrounding tissues. However, one
property that will likely be shared by all examples mentioned as well as functional
amyloid proteins yet to be discovered is a high degree of regulation. It is our hope that
future studies will not only reveal additional mechanisms of regulation governing the
conversion of functional amyloid proteins from non-amyloid to amyloid forms but also
highlight processes that may be misregulated in amyloid disease.

1.2.4 PMEL amyloid
Melanosomes are lysosome-related organelles that mature from early endosomes in four
morphologically distinct stages. Stage I melanosomes are characterized by intraluminal
vesicles (ILVs) from which short fibrillar structures appear to emanate (Figure 1.3; (60)).
Lateral association of these fibrils occurs as the organelle matures to stage II. Thus stage
II melanosomes are characterized by the presence of longer, thicker fibrils arranged in
parallel sheets (Figure 1.3; (60)). As the organelle continues to mature, melanins are
synthesized and deposited on these proteinaceous sheets until the underlying fibrillar
scaffold is completely obscured by the deposition of pigment.
Premelanosome protein (PMEL; also referred to as Pmel17, Silver, ME20, or gp100) was
originally identified as a component of the “melanosomal matrix” by antisera raised
against the Triton X-100 insoluble fraction of melanosomes that (1) labeled the
13

	
  
Figure 1.3

Melanosome maturation. Cells from a pigmented human melanoma cell line, MNT-1,
were analyzed by thin section electron microscopy. Note the cytoplasmic coats on the
limiting membrane and fibrils extending from ILVs in stage I melanosomes, the parallel
sheets of amyloid present in stage II melanosomes, the deposition of melanins in stage III
melanosomes, and how the underlying melanosomal matrix is masked in stage IV
melanosomes. Scale bar, 200 nm. Adapted from: Electron tomography of early
melanosomes: implications for melanogenesis and the generation of fibrillar amyloid
sheets (60).
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melanosomal matrix of B16 mouse melanoma cells and (2) immunoprecipitated a fulllength protein that was soluble in Triton X-100 as well as a proteolytically processed
form of PMEL that required the harsher detergent SDS to be solubilized (61). This was
subsequently supported by experiments showing an interaction between PMEL with
newly synthesized melanin polymers (62) as well as additional immuno-electron
microscopy studies in MNT-1 human melanoma cells that showed clear labeling of fibrils
within stage II melanosomes (9). Importantly, PMEL is both necessary and sufficient for
fibril formation. Fibrillar structures are absent from the melanosomes of PMEL knockout
mice (63), while expression of PMEL cDNA is sufficient to support fibril formation in
non-pigment cells (64). Together, these data indicate that PMEL is the primary
component of the fibrillar structures observed in early stage melanosomes.
It is now known that the fibrils formed by PMEL are in fact functional amyloid.
Recombinantly produced PMEL fragments purified from E. coli inclusion bodies using 8
M guanidinium hydrochloride rapidly assemble into fibrils following dilution into nondenaturing buffers (18). The fibrils are visible by electron microscopy, accelerate the rate
of melanin deposition in vitro, bind the amyloid dyes Thioflavin T and Congo Red, and
have the characteristic cross-β sheet X-ray diffraction pattern of amyloid (18). In vivo,
melanosomes isolated from bovine retinal pigment epithelia stain with Thioflavin S and
Congo Red, and the Thioflavin S staining overlaps with that of PMEL in detergentinsoluble clusters extracted from the bovine melanosomes (18).
As the first functional amyloid protein to be identified in mammals, PMEL was the first
to challenge the notion that functional amyloid proteins would be limited to more
15

	
  

primitive organisms due to the risk of forming large insoluble protein structures in
longer-lived multicellular species. Yet PMEL is highly conserved throughout vertebrate
evolution suggesting that the process of PMEL fibril formation is (1) regulated such that
very little of the protein adopts toxic/misfolded conformations and (2) so evolutionarily
beneficial as to be worth the risk.

1.2.5 PMEL regulation
PMEL fibril formation must be constrained to a specific time and place because
unregulated amyloid formation could rapidly wreak havoc on both melanocytes and the
organism as a whole. Without a doubt, many redundant layers of regulation exist to
prevent such a catastrophe; however, only a small handful of these layers have been
identified. Understanding more of these layers will help us determine whether the
regulatory mechanisms that govern functional amyloid formation are shared by
pathological amyloid proteins and perhaps shed some light on what makes pathological
amyloid proteins so devastating in patients with neurodegenerative disease.

Tissue-specific expression
Of the regulatory mechanisms that have been identified, the pigment-cell-specific
expression of PMEL is the most straightforward. Under control of the microphthalmiaassociated transcription factor (MITF) (65), PMEL is expressed only in those cells that
produce eumelanin: pigment cells of the skin, eye, heart, and inner ear. Note that the
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production of pheomelanin pigments does not involve MITF, PMEL, or the production of
amyloid fibrils (66,67).

Compartmentalization
Regulatory mechanisms also exist to ensure that PMEL forms amyloid only on
intraluminal vesicles (ILVs) of early endosomes/stage I melanosomes. PMEL is initially
synthesized in the ER as a type I transmembrane protein (Figure 1.4; (68-70)). Once
folded, PMEL traffics through the Golgi where O-linked glycans are added and 3 of the 4
N-linked glycans mature to the complex type (64,71,72). PMEL is then cleaved by a
proprotein convertase in the TGN (73) and/or in endosomes (74), and at least some
quantity of PMEL traffics to the plasma membrane (75). At the plasma membrane, a
small fraction of PMEL is released into the extracellular space by ectodomain shedding
(76), while the rest is taken back up into the cell and targeted to clathrin-coated early
endosomes/stage I melanosomes via a dileucine-based sorting signal in the cytoplasmic
domain of the protein (77). Within stage I melanosomes, PMEL is sorted to ILVs in a
process dependent on CD63 and ApoE but not ESCRT components (78,79) and cleaved
by BACE2 (80). The protein then assembles into amyloid fibrils that can be seen
emanating from ILVs by electron microscopy. The fibrils then associate laterally to form
parallel sheets of amyloid in stage II melanosomes. As the melanosomes mature,
melanins are synthesized and deposited on the fibrillar PMEL scaffold, forming stage III
melanosomes. These pigmented stage III melanosomes ultimately mature to stage IV
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Figure 1.4

Trafficking of PMEL from the ER to stage I melanosomes. Schematic showing PMEL
as it traffics from its site of synthesis in the ER to stage I melanosomes. At least a
fraction of PMEL transits through the Golgi, TGN, and plasma membrane en route to
stage I melanosomes. Adapted from: PMEL: a pigment cell-specific model for functional
amyloid formation (6) by B. Watt.
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melanosomes which have so much melanin that the underlying PMEL scaffold can no
longer be visualized by electron microscopy or detected using PMEL antibodies (9).
Notably, PMEL amyloid fibrils are not observed in the ER, Golgi, trans-Golgi network
(TGN) or any organelle preceding early endosomes/stage I melanosomes. Therefore, the
conformational switch that converts PMEL from a non-amyloid protein to an amyloid
protein likely occurs in association with ILVs or membranes that later invaginate to form
ILVs. Several properties of ILVs could aid in this conversion. Association with lipids of a
specific composition or curvature may be required to partially unfold and/or stabilize a βsheet rich conformation of PMEL – a hypothesis strengthened by the new link between
PMEL and ApoE, a protein that not only coats lipoprotein particles but alleles of which
are a risk factor for AD (81). Additionally, the presence of proprotein convertases (82),
BACE2 (80), ADAM proteases (83), and/or cysteine proteases (see chapter 2) in an
environment favorable for their activity may facilitate this process. Chaperones or other
regulatory mechanisms designed to prevent premature fibril formation elsewhere in the
cell could also simply be absent in ILVs, and concentrating PMEL monomers into a
small patch of membrane likely facilitates nucleation. Regardless, the secreted form of
PMEL is soluble (64,84,85) and does not form fibrils in the culture medium (unpublished
results) suggesting that the environment of ILVs is necessary for the conversion of PMEL
from a non-amyloid to an amyloid form. Restricting the formation of PMEL amyloid to a
specific membrane-enclosed organelle likely decreases the potential for toxicity arising
from interactions between cytosolic proteins and misfolded oligomers, nonfibrillar
aggregates, protofibrils, and/or the completed PMEL matrix.
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Kinetics
A toxic intermediate with a short half-life may have fewer opportunities to interact with
other cellular components and cause damage than one with a longer half-life. Therefore,
extremely rapid polymerization kinetics have been proposed as one mechanism by which
functional amyloid proteins avoid the toxic effects observed with the formation of
pathological amyloid. In vitro, recombinant PMEL purified using 8 M guanidinium
hydrochloride forms fibrils within 3 s of dilution into a non-denaturing buffer (18). While
the kinetics of PMEL fibril formation is difficult to measure in vivo, metabolic pulsechase experiments indicate that the entire process – from translation in the ER to
polymerization into insoluble amyloid fibrils – occurs in a matter of hours.
Rapid fibril formation that occurs within seconds has also been observed for
recombinantly produced CPEB (58). This is in contrast to the hours or days required for
synthetic Aβ42 to form fibrils without seeding (25). Intriguingly, the functional amyloid
protein RIP1/RIP3 also took hours to polymerize into amyloid fibrils after dilution into
non-denaturing buffer (17) suggesting that this mechanism of regulation may not be
shared among all functional amyloid proteins.

Cleavage
At least two regulated proteolytic cleavage events are absolutely essential for PMEL
fibril formation. A furin-like proprotein convertase cleaves full-length PMEL into two
fragments: an N-terminal Mα fragment and a C-terminal Mβ fragment (82). The Mα
fragment contains the fibril-forming domains of PMEL and can be incorporated into
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insoluble amyloid fibrils without additional processing (82,86). The Mβ fragment
contains a cysteine-rich luminal domain (the KLD; see below), transmembrane domain,
and cytoplasmic domain. Since Mα and Mβ are connected by at least one disulfide bond
(8), subsequent cleavage by an ADAM protease at the plasma membrane (76) or by
BACE2 within endosomes (80) is required to generate soluble PMEL. In this second
cleavage step, Mβ is cleaved into an Mβ’ fragment that is covalently associated with Mα
to form the soluble Mα+Mβ’ species and a C-terminal fragment (CTF) that contains the
transmembrane and cytoplasmic domains and is eventually degraded in lysosomes via an
ESCRT-dependent process (78).
The PMEL primary structure can be subdivided into several domains (see Figure 2.1A).
The very N-terminus of PMEL contains a 23-amino-acid signal sequence (69,87) that
targets the protein for translocation into the ER. Adjacent to the signal sequence is an Nterminal region (NTR) that is necessary for both the trafficking of PMEL to ILVs and for
the formation of functional amyloid fibrils (74). Other than a homologous region in the
GPNMB protein (88), the NTR has no identifiable conserved characteristics except for
three N-linked glycosylation sites and three cysteine residues that might participate in
disulfide bonds (see below). Also required for both PMEL trafficking and fibril
formation, the polycytic kidney disease (PKD) domain has homology to a repeated βsheet-rich domain of polycistin-1, a protein in which mutations lead to polycystic kidney
disease. The last domain present in the Mα region of PMEL is the RPT domain, a highly
glycosylated region of the protein containing 7-10 imperfect repeats of a 13-amino-acid
sequence (71,89). The RPT domain is highly modified by O-linked sialylated glycans in
the mature PMEL protein, and although conserved in nature and position, this domain is
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not conserved in sequence across vertebrate evolution. A recombinant form of the RPT
domain, produced in bacteria and lacking O-linked glycans, has been shown to produce
amyloid structures when incubated at low pH for prolonged periods of time, but unlike
physiological PMEL amyloid, these structures dissolve at neutral pH (90-93).
Proprotein convertase cleavage occurs in the TGN (73) and/or in endosomes (74) and is
required for the formation of PMEL amyloid fibrils. If the cleavage site is mutated or
proprotein converatase cleavage is inhibited using α1-antitrypsin Portland (α1-PDX), a
furin-specific variant of α1-antitrypsin, PMEL forms disordered electron-dense
aggregates instead of the usual parallel arrays of amyloid visible by electron microscopy
(82).
Within pigment cells, BACE2 cleavage releases Mα+Mβ’ into the lumen of early
endososomes/stage I melanosomes (80). Interestingly, BACE2 is a homolog of BACE1,
the enzyme that cleaves and defines the N terminus of Aβ. However, BACE2 knockout
mice are hypopigmented whereas BACE1 knockout mice are not (80), suggesting that
only BACE2 functions in melanosome maturation. Indeed, when BACE2 was depleted
by siRNA, the number of fibril-containing organelles decreased threefold and the number
of organelles containing unstructured aggregates increased sixfold in thin sections
examined by electron microscopy (80). By electron tomography, some small fibrils were
visible in the BACE2-depleted cells; however, none of these fibrils were organized into
the parallel sheets observed in control cells. Together, these data indicate that BACE2
cleavage is required for the efficient assembly of PMEL amyloid fibrils.
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Summary
Regulatory mechanisms ensure that the conversion of PMEL from a non-amyloid to an
amyloid form occurs in a manner beneficial to the organism. So far, we know that PMEL
must be expressed and appropriately cleaved to rapidly assemble into amyloid fibrils on
ILVs within pigment cells. However, it is not known how – or if – the KLD contributes
to the regulation of PMEL amyloid formation. Therefore, in chapter 2 we examine the
role of disulfide bonding, dimerization, and the KLD in regulating when and where
PMEL is transformed into functional amyloid.

1.3 Stage III and stage IV melanosomes
Once PMEL has been appropriately cleaved and assembled into sheets of functional
amyloid, the delivery of additional melanosomal cargo results in the maturation of these
unpigmented stage II melanosomes to pigmented stage III and stage IV melanosomes
(Figure 1.2). Both enzymes responsible for the synthesis of melanin and proteins that
alter the environment of the melanosome to optimize enzymatic activity must be present
to achieve full pigmentation. Defects in any of these proteins leads to hypopigmentation
of the skin and eyes in a group of disorders collectively known as oculocutaneous
albinism (94).

1.3.1 Melanosomal proteins associated with oculocutanous albinism
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Oculocutaneous albinism type 1 (OCA1) is caused by mutations in tyrosinase (TYR), the
rate-limiting enzyme in the synthesis of melanins (95). TYR is an integral membrane
protein synthesized in the ER (96) with two copper binding sites (97). Copper is supplied
to apo-tyrosinase by the copper transporter ATP7A, which pumps copper from the
cytosol into the lumen of the TGN or endosomal compartments (98). Therefore,
tyrosinase is transiently active when loaded with copper in the TGN but loses its copper
cofactors prior to its arrival in stage III melanosomes. Therefore, a cohort of ATP7A
must be delievered to melanosomes in melanocytes to resupply TYR with copper for full
enzymatic activity (10). When ATP7A delivery is impaired, as it is in some forms of
HPS, TYR is inactive and melanosome maturation is suspended at stage II.
Oculocutanous albinism type 2 (OCA2) is caused by mutations in the OCA2 protein (also
known as pink-eyed dilution or P protein), a chloride-sensitive ion channel (13) that
regulates melanosomal pH. The internal pH of a melanosome rises as the organelle
matures (9). Endosomes, from which melanosomes are derived, generally have an
internal pH between 5 and 6 (99). This low pH is important for proprotein convertase
activity but may also facilitate PMEL fibril formation by destabilizing the protein and
promoting conformational change (8). However, optimal TYR activity requires a pH of
6.8 (7,100). Therefore, the pH of melanosomes must increase for maximum pigment
production.
Specialized transporters such as OCA2 neutralize the acidic pH of early stage
melanosomes. In the absence of OCA2, melanosomes are hypopigmented. However,
treatments that increase melanosomal pH restore pigmentation in OCA2-deficient
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melanocytes (101). In addition, exogenous expression of OCA2 in non-pigment cells
raises the pH of endosomes and lysosomes (13).
Oculocutaneous albinism type 3 (OCA3), also known as rufous oculocutaneous albinism,
is caused by mutations in tyrosinase-related protein 1 (TYRP1), a protein that directly or
indirectly facilitates the conversion of DHICA to eumelanin (102). Patients with OCA3
therefore have a higher ratio of pheomelanin to eumelanin, resulting in reddish skin and
hair.
None of the proteins associated with oculocutanous albinism type 4, 5, 6, or 7 are very
well characterized. Oculocutaneous albinism type 4 (OCA4) is caused by mutations in
SLC45A2, a 12-transmembrane domain H+-sucrose symporter (103). The exact gene
associated with oculocutaneous albinism type 5 (OCA5) has yet to be identified (104).
Oculocutaneous albinism type 6 (OCA6) is caused by mutations in SLC24A5 (11), a
sodium/calcium exchanger that localizes to the TGN, and oculocutaneous albinism type 7
(OCA7) is caused by mutations in the uncharacterized orphan gene, C10orf11 (105).
Given the phenotype of patients with these disorders, however, each one must contribute
in some way to melanosome maturation or melanin biosynthesis.

1.3.2 Trafficking of melanosomal cargo
Melanosomes rely on specialized cellular machinery for the delivery of TYR and other
melanosome-specific proteins. Proteins that traffic directly to mature melanosomes such
as TYR, TYRP1, and OCA2 typically contain acidic dileucine-based motifs
[D/E]XXXL[L/I] (14,106,107) that bind to AP-1 in the TGN and/or AP-3 in endosomes
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(14,108-110). These adaptor proteins then direct TYR, TYRP1, and OCA2 into clathrincoated vesicles for delivery to melanosomes in a process that requires the biogenesis of
lysosome-related organelles complexes BLOC-1 and BLOC-2 (111-113).
However, some melanosomal proteins including dopachrome tautomerase (DCT) and
SLC45A2 lack dileucine-based motifs. While the mechanisms regulating the transport of
these two proteins have not been closely examined, both proteins have cytoplasmic
tyrosine-based Yxxϕ sorting motifs and tyrosine-based motifs have been shown to bind
the µ subunits of AP-1 and/or AP-3 (114). Therefore, in chapter 3, we test whether
mutation of the critical tyrosine residue in the Yxxϕ sorting motif affects the steady-state
localization of SLC45A2.

1.3.3 SLC45A2
Very little is known about the localization, trafficking, or function of SLC45A2.
SLC45A2 expression in yeast resulted in proton-dependent sucrose uptake (103).
However, one paper reported that the protein localizes to BLOC-1 trafficking
intermediates (115), another suggested localization to early stage melanosomes (116),
and yet another rudimentary study found co-localization of SLC45A2 with both early and
late stage melanosomes (117). Likewise, one study suggested that SLC45A2 functions in
trafficking TYR to melanosomes (118), while another implicated SLC45A2 in the
regulation of melanosomal pH. (119). Therefore, in chapter 3, we thoroughly examine the
localization of a functional HA-tagged variant of SLC45A2 and present preliminary data
that suggest SLC45A2 facilitates sustained TYR activity by maintaining a neutral pH.
26

	
  

1.4 Dissertation Aims
Melanosomes are lysosome-related organelles with a unique complement of proteins
specialized for the synthesis and storage of pigments. In early stage melanosomes, a
fibrillar matrix is assembled in preparation for melanin biosynthesis. This matrix is
comprised primarily of the functional amyloid protein PMEL, which must traverse the
secretory pathway in a non-amyloid form prior to its polymerization into amyloid fibrils
in stage I and stage II melanosomes. In stage III and stage IV melanosomes, transporters
optimize conditions within the organelle for the production of melanins. One pigment
cell-specific transporter, SLC45A2, is hypothesized to contribute to this process by
trafficking to the melanosomal membrane and helping to regulate melanosomal pH;
however, studies performed prior to the beginning of this thesis were at best suggestive of
these findings. We thus pursued the following questions:

Question 1: What regulates the conversion of PMEL from a non-amyloid to an
amyloid protein? The difference between functional amyloid and pathological amyloid
may lie in regulatory mechanisms that prevent and/or encourage amyloid formation
within the cell. However, our understanding of the molecular mechanisms that govern
functional amyloid formation is far from complete. For instance, proprotein convertase
and BACE2 cleavage are required for PMEL fibril formation since inhibition of either
cleavage event results in disordered aggregates by electron microscopy; however, other
factors must regulate the assembly of PMEL amyloid fibrils as proteolytically processed,
secreted forms of PMEL are soluble.
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We hypothesize that disulfide bonds promote a non-amyloid conformation of PMEL,
thereby preventing unwanted fibril formation early in the secretory pathway. The
formation and resolution of disulfide-stabilized PMEL species is discussed in chapter 2
where we show that dimerization may inhibit PMEL amyloid formation en route to
melanosomes.

Question 2: How does SLC45A2 contribute to melanosome maturation? Mutations in
human SLC45A2 result in oculocutaneous albinism type 4; therefore, it stands to reason
that the protein is necessary for efficient melanin biosynthesis. In chapter 3, we determine
the localization of a functional HA-tagged variant of SLC45A2 and show that the H+sucrose symporter requires a cytoplasmic tyrosine-based Yxxϕ sorting motif to traffic
appropriately. We also discuss some preliminary data suggesting a requirement for
SLC45A2 in maintaining a neutral environment during late stages of melanosomal
maturation.
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Dimerization prevents PMEL functional amyloid formation in early secretory
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ABSTRACT
The formation of functional amyloid must be carefully regulated to prevent the
accumulation of potentially toxic products. Premelanosome protein (PMEL) forms nontoxic functional amyloid fibrils that assemble into sheets upon which melanins ultimately
deposit within the melanosomes of pigment cells. PMEL is synthesized in the
endoplasmic reticulum (ER) but forms amyloid only within post-Golgi melanosome
precursors; thus, PMEL must traverse the secretory pathway in a non-amyloid form.
Here, we identify a native disulfide-bonded PMEL dimer that impedes premature fibril
formation early in the secretory pathway. Analyses by non-reducing SDS-PAGE, size
exclusion chromatography, and sedimentation velocity revealed two native high Mr
disulfide-bonded species that contain Golgi-modified forms of PMEL. These species
correspond to disulfide bond-containing dimeric and monomeric PMEL isoforms that
contain

no

other

proteins

as

judged

by

2D-PAGE

of

metabolically

labeled/immunoprecipitated PMEL and by mass spectrometry of affinity-purified
complexes. Metabolic pulse-chase analyses, small molecule inhibitor treatments, and
evaluation of site-directed mutants suggest that the PMEL dimer forms around the time
of ER exit and is resolved by disulfide bond rearrangement into a monomeric form within
the late Golgi or in a post-Golgi compartment. Mutagenesis of individual cysteine
residues within the non-amyloid cysteine-rich Kringle-like domain stabilizes the
disulfide-bonded dimer and impairs functional amyloid fibril formation as determined by
electron microscopy. Our data suggest that PMEL dimerization helps prevent premature
fibril formation in early secretory compartments and that resolution of the dimer must
occur prior to the assembly of functional amyloid fibrils.
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INTRODUCTION
Amyloid is a "cross beta sheet" polymeric protein conformation in which beta strands are
stacked perpendicularly to the long axis of the amyloid fibril (19). The amyloid fold is
traditionally associated with pathological protein misfolding in neurodegenerative
diseases such as Alzheimer and Parkinson diseases (120). However, the amyloid fold has
also been exploited for diverse physiological processes in a wide range of organisms (41)
including biofilm formation in bacteria (16), learning and memory in Drosophila (42),
and programmed necrosis in mammals (17). Molecular mechanisms that limit the toxicity
of such “functional amyloids” or their folding intermediates during synthesis are
incompletely understood, but likely regulate when and where these proteins assemble into
amyloid fibrils. For example, curli biofilm formation in E. coli is regulated by three
proteins: CsgB, CsgC, and CsgF. CsgB is a minor curli subunit required to nucleate
amyloid fibril formation in vivo (44). CsgC is a chaperone protein that prevents
premature amyloid formation in the bacterial periplasm (46), and CsgF is an extracellular
protein important for the attachment of curli fibers to the cell surface (45). However,
much less is known about functional amyloid regulation in mammals where the formation
of large, self-assembling, insoluble protein structures likely carries increased risk due to
the multicellular nature and longer lifespan of higher organisms.
The best characterized mammalian functional amyloid protein is premelanosome protein
(PMEL; also referred to as Pmel17, Silver, ME20, or gp100). Within immature
melanosomes of pigment cells in the skin and eye, PMEL polymerizes into amyloid
fibrils (18) that associate laterally into sheets upon which melanins deposit as they are
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synthesized during melanosome maturation (reviewed in (6)). The amyloid sheets are
critical determinants of the ellipsoid melanosome shape (63,77), which has been shown to
be required for proper melanosome motility into the apical processes of retinal pigment
epithelial cells (121). The amyloid sheets have also been proposed to accelerate melanin
polymerization (18,122,123), and organisms that lack PMEL or carry mutations in the
PMEL gene are characterized by various degrees of hypopigmentation (63,124-128).
Because PMEL is synthesized in the endoplasmic reticulum (ER) as a type I
transmembrane protein (68-70) but only initiates amyloid fibril formation within the
lumen of endosomal membrane compartments (60,64,129), PMEL must navigate the
secretory pathway from the ER to endosomes in a non-amyloid form. It is thus an
excellent model system in which to dissect the regulation of amyloid formation within the
endomembrane system.
Our current understanding of the processes involved in PMEL biosynthesis and
amyloidogenesis is as follows. Following synthesis and addition of four core N-linked
glycans within the ER (generating a “P1” precursor form), PMEL is exported to the Golgi
where it is extensively modified by O-glycosylation (71,72) and maturation of the Nlinked glycans to the complex type (64). This generates a full-length “P2” form that is
subsequently cleaved by a proprotein convertase into two disulfide-linked fragments, Mα
and Mβ (82), either in the trans Golgi network (73) or within endosomes (74) (see Figure
2.1A). A subsequent proteolytic cleavage by BACE2 within endosomes (80) or by an
ADAM protease at the plasma membrane (76) cleaves Mβ into two fragments; the Cterminal fragment (CTF) contains the transmembrane domain and is eventually degraded
in a γ-secretase-dependent manner in lysosomes (78), while the other fragment (Mβ’) is
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liberated from the membrane covalently bound to Mα (80,84). No longer anchored to the
membrane, most of the Mα undergoes additional proteolytic processing events prior to
forming the parallel arrays of functional amyloid fibrils characteristic of early stage
melanosomes (60,72,130). A small fraction of Mα may also be secreted (64,84) or
directly incorporated into growing fibrils without further processing (82,86). Proprotein
convertase and BACE2 cleavage are necessary for functional amyloid fibril formation
since interference with either of these two proteolytic processing events results in the
formation of disordered PMEL aggregates instead of ordered fibrils (80,82). However,
these cleavage events are not sufficient to induce fibril formation since a fraction of
cleaved PMEL is secreted from cells in culture (64,84,85) in a non-amyloid form
(unpublished results). Therefore, additional regulatory mechanisms must govern PMEL
fibril formation.
Regulated disulfide bond rearrangements have the potential to affect both protein
conformation and protein function. For example, interaction of the β-barrel protein LptD
with the LptE subunit of the LPS translocon in the E. coli outer membrane triggers a
disulfide bond rearrangement within LptD that activates the translocon (131). PMEL has
13 cysteine residues (black circles, Figure 2.1A), of which 11 are exposed to the lumen
of the endomembrane system and thus might participate in disulfide bonds. Indeed, the
existence of intermolecular disulfide bonds can be inferred from experiments showing
that P2 and non-fibrillar Mα and Mβ fragments are incorporated into higher order
oligomers when samples are analyzed by non-reducing SDS-PAGE (64). Here we show
that disulfide bonds maintain PMEL in a tethered oligomeric form that is incompatible
with amyloidogenesis. Our data suggest that generation and destruction of a disulfide33

	
  

stabilized dimer contributes an additional layer of regulation to the timing of PMEL
amyloid formation.

RESULTS
p250 and p160 are disulfide-bonded species composed of Golgi-modified PMEL
The Golgi-matured P2 form of PMEL and the products of proprotein convertase
cleavage, Mα and Mβ (Figure 2.1A), migrate with Mr of approximately 120,000,
100,000, and 28,000, respectively, when analyzed by reducing SDS-PAGE (64,130).
However, when analyzed by non-reducing SDS-PAGE, most detergent-soluble forms of
Golgi-matured PMEL migrate with a higher Mr (64), indicating that the vast majority of
pre-amyloid P2, Mα, and Mβ isoforms exist as components of disulfide-bonded species.
To further investigate the nature of these species, immunoblots were performed using
antibodies that can distinguish between immature and mature PMEL isoforms. MNT-1
human melanoma cells (which endogenously express PMEL) or transfected HeLa cells
transiently expressing full-length PMEL (isoform 1) were treated with NEM prior to and
during lysis in TritonX-100 to prevent the formation of artifactual disulfide bonds.
Detergent-soluble lysates were then fractionated by SDS-PAGE on low percentage
polyacrylamide gels under non-reducing (NR) or reducing (R) conditions and analyzed
by immunoblotting using the antibodies HMB45, αPMEL-I, αPMEL-N, or αPMEL-C.
The HMB45 monoclonal antibody recognizes the O-glycosylated RPT region of mature
PMEL isoforms present only in post-Golgi compartments (72,132). The αPMEL-I
antibody recognizes the same domain in its non-glycosylated form as is characteristic of
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Golgi-matured PMEL exists predominantly in high Mr disulfide-bonded species. (A)
Schematic diagram of the mature PMEL primary structure showing the sites of antibody
recognition for αPMEL-N, αPMEL-I, HMB45, and αPMEL-C (note that αPMEL-I
recognizes only the immature form of PMEL lacking O-glycans), cleavage sites for a
proprotein convertase (PC) and BACE2, and resulting cleavage fragments Mα, Mβ, Mβ’,
and C-terminal fragment (CTF). Also noted are the domain structure, N-linked
glycosylation sites (green triangles; double triangles indicate sites that are modified to the
complex type in the Golgi), O-linked glycosylation sites (blue clovers), and cysteine
residues (black circles). The N-terminal region (NTR), a region with homology to a
repeated domain in polycystin 1 (PKD), a highly glycosylated repeat (RPT) domain, and
the Kringle-like Domain (KLD) are indicated in light gray, and the transmembrane
domain (TM) is indicated in blue. (B-E) MNT-1 melanoma cells (MNT, lanes 1 and 3) or
transiently transfected HeLa cells (HeLa, lanes 2 and 4) expressing wild-type PMEL
were lysed in buffer containing 1% (w/v) Triton X-100, and the soluble material was
fractionated by SDS-PAGE under non-reducing (NR) or reducing (R) conditions.
Proteins transferred to membranes were then probed with the PMEL antibodies HMB45
(B), αPMEL-I (C), αPMEL-N (D), or αPMEL-C (E). The migration of molecular weight
standards is indicated to the right of each blot. Bands corresponding to p250, p160,
p160*, Mα+Mβ’, Mα, immature PMEL conformers (cfmrs), and P1 are indicated by
arrows; note that Mα and P1 comigrate in MNT-1 cells. *, an alternatively spliced PMEL
product (PMEL-ss). Lane numbers are indicated at bottom.
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immature PMEL isoforms located in the ER (133). The αPMEL-N and αPMEL-C
antibodies recognize the N-terminus and C-terminus of PMEL, respectively, regardless of
maturation status (64,133).
Under non-reducing conditions, HMB45 detected two major species that migrate with Mr
of approximately 160,000 (p160) and 250,000 (p250). Also detected were larger PMEL
species retained at the boundary between the stacking and separating gel and minor
amounts of p160*, Mα+Mβ’, and free Mα (Figure 2.1B, lanes 1-2). The p160* species is
a slightly faster migrating version of p160 resulting from an alternatively spliced PMEL
variant expressed in melanocytic cells but not transfected HeLa cells (133). The Mα+Mβ’
species is composed of Mα covalently bound to Mβ’ based on the following: (i) its
detection by the HMB45 and αPMEL-N antibodies but not the αPMEL-C antibody,
indicating that it lacks the PMEL C-terminus; (ii) its comigration with the major form of
secreted PMEL (see Figure 2.5A), which consists predominantly of disulfide-bonded
Mα+Mβ’ complexes (84); and (iii) its depletion following inhibition of BACE2 (see
Figure 2.7A), the enzyme that cleaves Mβ into CTF and Mβ’ fragments. Since only a
single band corresponding to Mα is observed under reducing conditions (Figure 2.1B,
lanes 3-4; note that Mα migrates with a higher Mr when derived from MNT-1 cells than
when derived from HeLa cells due to differences in terminal glycosylation (64)),
disulfide bonds must be necessary to maintain the integrity of p250 and p160 as well as
that of p160* and Mα+Mβ’.
The p250 and p160 bands were not labeled by αPMEL-I under non-reducing conditions;
instead, this antibody detected a band that corresponds to monomeric P1 as well as a
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series of high Mr bands ranging from approximately 220,000 to the top of the separating
gel (Figure 2.1C, lanes 1-2). Since the high Mr bands collapse into P1 under reducing
conditions (Figure 2.1C, lanes 3-4; note that the slightly faster migrating band *
corresponds to the P1 form of the alternatively spliced PMEL variant, PMEL-ss (133)),
these species most likely represent partially folded disulfide-bonded conformers of
PMEL in the ER (cfmrs, Figure 2.1C). The αPMEL-N and αPMEL-C antibodies
recognized p250 and p160 as well as the immature PMEL conformers detected by
αPMEL-I, indicating that all of these high Mr species contain either full-length PMEL or
Mα disulfide-bonded to Mβ (Figure 2.1D, E). Therefore, only Golgi-matured forms of
full-length or proprotein convertase-cleaved PMEL are present in p250 and p160.
Furthermore, the presence of p250 and p160 both in MNT-1 cells that endogenously
express PMEL and in non-pigment HeLa cells expressing a PMEL transgene suggests
that no additional pigment cell-specific proteins are required for the formation of mature
disulfide-bonded PMEL species.

p250 and p160 represent distinct physiological complexes
To test whether the disulfide-bonded p250 and p160 species observed by non-reducing
SDS-PAGE correspond to physiological PMEL-containing complexes, we assessed the
biophysical properties of p250 and p160 under non-denaturing conditions. First, we
examined the PMEL species by sedimentation velocity analysis. Lysates of MNT-1 cells
were prepared using n-octylglucoside, a non-ionic detergent with a small micelle size and
a relatively high partial specific volume (134). After fractionation through sucrose
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gradients containing n-octylglucoside, mature PMEL species were identified by
immunoblot analysis of gradient fractions separated by non-reducing SDS-PAGE
(Figure 2.2A). Sedimentation coefficients were then calculated by comparing the peak
position of mature PMEL species, detected using the HMB45 antibody, with the peak
position of globular protein standards (Figure 2.2B, C). Distinct sedimentation
coefficients were calculated for p250, p160, Mα+Mβ’, and “free” Mα. Consistent with
the relative order of their migration by non-reducing SDS-PAGE, p250 had the highest
calculated s value followed by p160, Mα+Mβ’, and lastly free Mα. This suggests that
p250 and p160 are not artifacts of non-reducing SDS-PAGE but distinct native disulfidebonded PMEL complexes. The sedimentation coefficients of all four PMEL species were
substantially smaller than expected given the magnitude of their migration by nonreducing SDS-PAGE (Table 2.1), suggesting that these species might have extended
glycoprotein structures.
To further characterize the PMEL species under native conditions, MNT-1 cell lysates
were fractionated by size exclusion chromatography in n-octylglucoside. Aliquots of each
fraction were separated by non-reducing SDS-PAGE, and mature PMEL species were
detected by immunoblotting with HMB45. As observed in the sedimentation analyses,
the four PMEL species – p250, p160, Mα+Mβ’ and Mα – migrated with distinct elution
volumes by size exclusion chromatography (Figure 2.3A, B). However, when the peak
elution volume of each species was compared with that of globular protein standards, the
mature PMEL species had peak elution volumes much smaller – and therefore Stokes
radii much larger – than expected for globular proteins of similar molecular weight
(Figure 2.3C, Table 2.1). For example, the Stokes radius of p250 (10.4 nm) was
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Figure 2.2

p250, p160, and Mα monomers have distinct sedimentation properties. MNT-1 cell
lysates prepared using 250 mM n-octylglucoside were subject to sedimentation velocity
analyses in 5-20% sucrose gradients. (A) Aliquots of the gradient fractions were analyzed
by non-reducing (NR) SDS-PAGE and immunoblotted using HMB45. Shown are regions
of the immunoblots corresponding to p250, p160, Mα+Mβ’, and Mα as indicated to the
left. Fraction numbers are indicated above each lane (bottom of the gradient is to the left;
top of the gradient is to the right), and the migration of globular protein standards IgG
and ovalbumin are indicated with arrows at top. Immunoblot contrast was optimally
adjusted for each individual species. (B) HMB45 immunoreactivity was quantified to
determine the peak elution fraction for p250, p160, Mα+Mβ’, and Mα. The lowest value
quantified for each species was set to 0% and the highest value was set to 100%. (C)
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Svedberg values were calculated for each species by comparison of peak fractions with
those of protein standards with known s values in three independent experiments. Circles,
values calculated from each experiment; open circles, values calculated from the
experiment shown in panels A and B; horizontal lines, mean value; error bars, standard
deviation. Mean and standard deviation are also shown in Table 2.1.
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Figure 2.3

p250, p160, and Mα monomers have distinct Stokes’ radii that are minimally
altered by solubilization in detergents with different micelle sizes. MNT-1 cells were
lysed using n-octylglucoside (A-C), dodecyl-β-D-maltoside (D-F), or Triton X-100 (G-I),
and the detergent extracts fractionated by size exclusion chromatography in the
corresponding detergent. (A, D, G) Eluted fractions were analyzed by SDS-PAGE under
non-reducing (NR) conditions and immunoblotted using the HMB45 antibody. Shown
are regions of the immunoblots corresponding to p250, p160, Mα+Mβ', and Mα as
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indicated to the left. Fraction numbers are indicated above each lane, and the migration of
α2-macroglobulin indicated with an arrow. Immunoblot contrast was optimally adjusted
for each individual species in each experiment. (B, E, H) HMB45 immunoreactivity was
quantified to determine the elution volume of p250, p160, Mα+Mβ’, and Mα. The lowest
value quantified for each species was set to 0% and the highest value was set to 100%.
(C, F, I) The Stokes radius of each species was then calculated by comparing the peak
elution fraction of that species with those of globular protein standards in three
independent experiments. Circles, values calculated from each experiment; open circles,
values calculated from the experiments shown in panels A, D, and G; horizontal lines,
mean value; error bars, standard deviation. Mean and standard deviation are also shown
in Table 2.1.
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Table 2.1

Stokes radius (nm)
Species

s20,w (S)

n-octylglucoside

dodecyl-β-Dmaltoside

Triton X-100

p250

6.15 +/- 0.20

10.38 +/- 0.34

9.82 +/- 0.16

10.09 +/- 0.07

p160

5.27 +/- 0.46

8.76 +/- 0.19

8.41 +/- 0.08

8.84 +/- 0.08

Mα+Mβ’

3.86 +/- 0.33

8.63 +/- 0.12

7.96 +/- 0.12

8.12 +/- 0.06

Mα

3.49 +/- 0.31

8.03 +/- 0.29

7.54 +/- 0.09

7.68 +/- 0.08

Summary of calculated sedimentation coefficients and Stokes radii.
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calculated to be larger than that of α2-macroglobulin (8.8 nm), a 720-kDa tetrameric
protein (135). To test whether the exceptionally large Stokes radii reflected association
with multiple detergent micelles, cell lysates were prepared and analyzed by size
exclusion chromatography using detergents with different micelle sizes: n-octylglucoside
(average micelle size of 8 kDa (136)), dodecyl-β-D-maltoside (average micelle size of
50-76 kDa (136)) or Triton X-100 (average micelle size of 81 kDa (137)). If any of the
PMEL species had been associated with multiple detergent micelles, those species would
have eluted with distinct volumes in each of the three detergents. However, the elution
volume of each PMEL species was roughly similar in all three detergents (Figure 2.3,
Table 2.1), suggesting that detergent micelles do not contribute substantially to the large
Stokes radii of the mature PMEL species. Therefore, the unusually high Stokes radii and
low sedimentation coefficients of p250, p160, Mα, and Mα+Mβ’ most likely reflect
extended glycoprotein conformations resulting from the heavily glycosylated RPT
domain of mature PMEL.

PMEL is the sole component of both p250 and p160
To determine whether p250 and p160 contain additional polypeptides besides PMEL, we
analyzed the contents of PMEL immunoprecipitates by 2-dimensional nonreducing/reducing SDS-PAGE (2D-PAGE). We used transfected HeLa cells transiently
expressing wild-type PMEL in this experiment because Mα is more clearly identified in
HeLa cell lysates analyzed by reducing SDS-PAGE. This is because, unlike melanocytic
cells, transfected HeLa cells typically do not express the alternatively spliced form of
45

	
  

PMEL (PMEL-ss) that comigrates with Mα by reducing SDS-PAGE (see Figure 2.1BD). In addition, Mα comigrates with P1 in MNT-1 cells but not in transfected HeLa cells
as a result of differences in terminal glycosylation. After extensively labeling
biosynthesized proteins with

35

S-methionine/cysteine, PMEL species in detergent cell

lysates were immunoprecipitated using αPMEL-N, αPMEL-C, or NKI-beteb (138) – a
monoclonal antibody to the PKD domain (72) – and then fractionated by 2D-PAGE and
analyzed by Phosphorimaging. Using this technique, the higher Mr bands observed by
standard SDS-PAGE (Figure 2.1) were resolved into their individual components.
Similar results were obtained using all three PMEL antibodies (Figure 2.4). Spots
corresponding to the core-glycosylated P1 and the Golgi-modified P2 forms of PMEL
were identified close to the diagonal and thus represent monomeric forms of these PMEL
species. The p160 band typically observed by 1-D non-reducing SDS-PAGE resolved
into two species by 2D-PAGE, one of which contained the Mα and Mβ products of
proprotein convertase cleavage and the other of which contained uncleaved, full-length,
Golgi-modified P2. The p250 band also resolved into both cleaved and uncleaved forms
of Golgi-modified PMEL. A number of other bands present in the non-reducing
dimension resolved into P1 under reducing conditions and thus most likely represent
disulfide-bonded ER folding intermediates. Importantly, no other radiolabeled
polypeptide was reproducibly detected within the p250 band or the p160 band.
Furthermore, three independent attempts to identify additional components by tandem
mass spectrometry analysis of affinity purified PMEL from MNT-1 cells yielded no
reasonable candidates other than chaperones and protein disulfide isomerases that were
present in vastly substoichiometric amounts (Table 2.2 and Supplemental Table S1)
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Figure 2.4

p250 and p160 are comprised of Golgi-matured P2 and Mα/Mβ fragments of PMEL.
Transiently transfected HeLa cells expressing wild-type PMEL were metabolically
labeled for 2 h with

35

S-methionine/cysteine, immunoprecipitated using αPMEL-N (A),

NKI-beteb (B), or αPMEL-C (C), and analyzed by 2D-PAGE under non-reducing
conditions in the first dimension (left to right; -BME) and reducing conditions in the
second dimension (top to bottom; +BME). The migrations of p250, p160, P2, and P1 in
the first dimension are indicated by arrows at the top; the migration of molecular weight
standards in the second dimension is indicated to the right of each blot; and the positions
of P2, P1, Mα and Mβ in the second dimension are indicated to the left.
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Table 2.2

Summed Intensity
10,459,000,000
9,310,000,000
3,643,900,000
2,444,500,000
1,113,200,000
1,060,400,000
1,052,500,000
908,870,000
720,070,000
477,000,000
431,880,000
352,060,000
351,310,000
350,080,000
292,260,000
264,970,000
248,250,000
194,490,000
161,510,000
152,110,000
125,550,000
120,610,000
117,270,000
113,980,000
112,810,000
105,730,000
100,700,000
100,210,000
97,113,000
86,599,000
70,376,000
67,557,000
65,533,000
64,584,000
64,038,000

Protein
PMEL
Trypsin (Sus scrofa)
AspN (Pseudomonas fragi)
Clathrin heavy chain 1
Mucin-19
Keratin, type I cytoskeletal 13
UDP-glucose:glycoprotein glucosyltransferase 1
Keratin, type II cytoskeletal 1
Trypsin
Keratin, type I cytoskeletal 10
Keratin, type II cytoskeletal 6A
Keratin, type II cytoskeletal 4
Keratin, type II cytoskeletal 2 epidermal
Methionine synthase
Solute carrier family 12 member 7
Filamin-A
Protein disulfide-isomerase A3
Myosin-9
Keratin, type I cytoskeletal 9
Endoplasmic reticulum resident protein 44
Kappa-casein (Bos taurus)
Ubiquitin
Unconventional myosin-Ic
Unconventional myosin-Id
Fatty acid synthase
Keratin, type I cytoskeletal 19
Vinculin
Protein disulfide isomerase A4
Transferrin receptor protein 1
4F2 cell-surface antigen heavy chain
78 kDa glucose-regulated protein (BiP)
Protein disulfide isomerase A6
Myosin-10
Ras GTPase-activating-like protein IQGAP1
Protein S100-A9
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MW (kDa)
120
24
16
188
357
50
175
66
15
59
60
57
65
135
119
280
57
227
62
47
21
10
118
116
273
44
117
73
85
65
72
48
231
189
13

	
  

61,131,000
60,047,000
54,174,000
54,029,000
44,466,000
43,245,000
42,124,000
40,829,000
39,343,000
36,125,000
34,172,000
32,707,000
32,563,000
31,993,000
31,932,000

Protein disulfide isomerase
Alpha-synuclein
Exportin-1
Small proline-rich protein 3
Keratin, type II cytoskeletal 5
Actin
Protein S100-A8
Heat shock protein beta-1
Tetraspanin-10
Solute carrier family 12 member 4
Annexin A1
Transcription elongation factor SPT5
Transmembrane protein 65
Filamin-B
Talin-1

57
14
123
17
62
42
11
23
36
119
39
121
25
276
270

Analysis of p250 and p160 by LC-MS/MS. Affinity-purified PMEL was fractioned on a
non-reducing SDS-PAGE gel, relevant bands excised and digested using trypsin or
AspN, and the samples analyzed by mass spectrometry. This table is a brief summary of
the top 50 “hits” obtained. Summed intensity refers to the sum of the eXtracted ion
currents from three independent experiments analyzing higher Mr disulfide-bonded
PMEL species. The proteins listed are of human origin unless otherwise noted. A more
detailed table with the results of each band analyzed in each of the three experiments is
provided in the supplemental Microsoft Excel file.
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and only associated with immature forms of PMEL (unpublished data). Other identified
peptides derived from either common contaminants, such as keratins, and/or from
proteins with molecular weights that were inconsistent with that of p250 and p160, or
were very poorly recovered relative to PMEL-derived peptides. We therefore conclude
that p250 and p160 are comprised exclusively of PMEL or PMEL fragments.
When considered together with the results from non-reducing SDS-PAGE, size exclusion
chromatography, and velocity sedimentation analyses, the simplest interpretation of our
data is that p250 represents a PMEL dimer and p160 represents a disulfide-dependent
conformation of a single PMEL monomer or Mα/Mβ complex.

p250 and p160 are intermediates of PMEL fibril formation
The reactivity of p250 and p160 with HMB45 but not with αPMEL-I suggests that these
two species are primarily present in post-ER compartments. In order to define the kinetics
of their formation, we performed a metabolic pulse/chase and immunoprecipitation
analysis.

MNT-1

cells

were

metabolically

labeled

for

15

min

with

35

S-

methionine/cysteine and then chased in medium containing excess unlabeled amino acids
for 0-120 min. PMEL isoforms in detergent-soluble cell lysates and the culture medium
from each time point were immunoprecipitated using NKI-beteb and analyzed by nonreducing or reducing SDS-PAGE. At the pulse, the primary PMEL species detected under
non-reducing conditions was monomeric P1, which migrated with a Mr of approximately
110,000 (Figure 2.5A, lane 1). The p250 band first appeared after 5 min of chase and
peaked at 30 min (Figure 2.5A, lanes 2-4). This resembles the kinetics of P2
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Figure 2.5

p250 and p160 are transient PMEL intermediates present only in cell lysates. MNT1 cells were metabolically labeled with

35

S-methionine/cysteine for 15 min and chased

for the times indicated (min). PMEL in detergent cell lysates or culture media, as
indicated, was then immunoprecipitated using NKI-beteb and fractionated by SDS-PAGE
under non-reducing (A) or reducing (B) conditions. The migration of molecular weight
standards is shown to the right of each gel. Bands corresponding to p250, p160,
Mα+Mβ’, P1, and Mα on the non-reducing gel and P2, P1, Mα, and Mβ on the reducing
gel are indicated by arrows; note that P1 and Mα largely comigrate. *, product of
alternatively spliced PMEL mRNA (PMEL-ss). Lane numbers are indicated at bottom.
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formation/accumulation, as observed under reducing conditions (Figure 2.5B, lanes 1-6),
suggesting that dimer formation occurs just prior to ER exit or in the early Golgi. The
p160 band was first observed after 15 min of chase and peaked at 30-60 min (Figure
2.5A, lanes 3-5). This resembles the kinetics of proprotein convertase cleavage, as
indicated by the appearance of the Mβ cleavage product observed under reducing
conditions (Figure 2.5B, lanes 1-6). Essentially similar results were obtained upon
pulse/chase analysis of PMEL expressed in transiently transfected HeLa cells (Figure
2.6). Thus, p160 is likely generated in the TGN or in a post-Golgi compartment.
Importantly, at no point did monomeric forms of P2 or Mα appear in cell lysates analyzed
under non-reducing conditions. This indicates that the vast majority of postER/prefibrillar PMEL must be present in disulfide bond-dependent intermediates.
As previously observed (64,70,84,138), a small fraction of PMEL was secreted into the
medium of MNT-1 cells starting at 30 min of chase and peaking at 120 min (Figure
2.5A, B, lanes 7-12). Completely consistent with those reports (84), PMEL secreted in
this manner was comprised primarily of Mα+Mβ’ with lesser amounts of free Mα.
To verify band identity and to probe for potential precursor-product relationships, MNT-1
cells were treated with small molecule inhibitors of trafficking and processing steps.
Detergent-soluble lysates were then analyzed by non-reducing SDS-PAGE and
immunoblotted with HMB45 or αPMEL-C. Treatment of MNT-1 cells with monensin, an
inhibitor of intra-Golgi transport (139), led to the accumulation of p250 and higher Mr
oligomers as well as the concomitant depletion of p160 (Figure 2.7A, B, lane 2). This
supports the conclusions that p250 forms during ER exit or in the early Golgi and that
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Figure 2.6

The kinetics of p250 and p160 formation in PMEL-expressing HeLa cells resembles
that of MNT-1 cells. Transiently transfected HeLa cells expressing wild-type PMEL
(long form) were metabolically pulse labeled with

35

S-methionine/cysteine for 10 min

and chased for the indicated amounts of time. Cell lysates prepared using Triton X-100
were then immunoprecipitated using αPMEL-C and fractionated by SDS-PAGE under
non-reducing (lanes 1-5) or reducing (lanes 6-10) conditions. The migration of molecular
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weight standards is shown to the right. Bands corresponding to p250, p160, and P1 on the
non-reducing gel and P2, P1, and Mα on the reducing gel are indicated to the left. Lane
numbers are indicated across the bottom.
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Figure 2.7

Potential precursor/procuct relationships among p250, p160, and Mα monomers.
(A, B) MNT-1 cells were untreated (lane 1) or treated for 3 h with 10 µM monensin (lane
2), 100 µM β-secretase inhibitor IV (lane 3), or 1 mg/mL E-64 (lanes 4 and 5). Cells
treated with E-64 were then either immediately harvested (lane 4) or additionally treated
with 10 µg/mL cycloheximide in the presence of E-64 for 2 h (lane 5). After lysis in
Triton X-100, detergent-soluble cell lysates were analyzed by non-reducing (NR) SDSPAGE followed by immunoblotting with HMB45 (A) or αPMEL-C (B). (C) MNT-1 cells
that were untreated (lane 1) or treated for 2 d with 1 mg/mL E-64 (lane 2) were lysed in
Triton X-100, and detergent-insoluble cell lysates were analyzed by reducing (R) SDSPAGE followed by immunoblotting with HMB45. The migration of molecular weight
standards is indicated to the left of each blot, and bands corresponding to p250, p160,
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Mα+Mβ’, Mα, P1, Mα’ fragments, and higher Mr multimers (mtmrs) are indicated with
arrows.
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p160 forms in the TGN or later. It also suggests that p250 might be the precursor of p160.
Treatment with β-secretase inhibitor IV at concentrations that inhibit BACE2 cleavage
(140) resulted in the substantial accumulation of p160 and the minor accumulation of
p250 and higher Mr oligomers (Figure 2.7A, B, lane 3). This result indicates that the
resolution of p160 – and perhaps a fraction of p250 – requires BACE2 cleavage, which is
known to cleave Mβ to Mβ’ and the CTF (80). Since BACE2 inhibition has been shown
to impede PMEL fibril formation (80), this also suggests that p160 cannot directly
assemble into functional amyloid fibrils. Lastly, treatment with the cysteine protease
inhibitor E-64 resulted in the accumulation of free Mα and Mα+Mβ’ (as detected by
HMB45 but not by αPMEL-C) but had no effect on p250 or p160 (Figure 2.7A, B, lane
4). Prolonged treatment with E-64 also resulted in the accumulation of Mα and the
depletion of Mα’ fragments in the detergent-insoluble fraction of MNT-1 cells (Figure
2.7C) suggesting that, in addition to ADAM proteases (83), cysteine proteases are
required to cleave Mα and Mα+Mβ’ into the Mα’ fragments that typically accumulate in
PMEL amyloid fibrils.
Importantly, treatment of these cells for an additional 2 hours in the presence of both E64 and the protein synthesis inhibitor cycloheximide (CHX) to allow for further
processing in the absence of new PMEL biosynthesis led to the depletion of p160 but not
of Mα or Mα+Mβ’ (Figure 2.7A, B, lane 5). This suggests that p160 is a true
intermediate in PMEL processing that precedes the formation of free Mα and Mα+Mβ’.
Finally, none of the inhibitor treatments (except for cycloheximide) affected the level of
P1 detected by αPMEL-C (Figure 2.7B) as is consistent with the notion that immature
PMEL monomers are predominantly located in pre-Golgi compartments (i.e. the ER).
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Cysteine 301 participates in a cross-subunit disulfide bond in p250 and a disulfide
bond between Mα and Mβ derived from the same PMEL precursor in p160
To determine which cysteine residues participate in the disulfide bonds that stabilize
p250 and p160, we evaluated the effect of single cysteine mutations on the disulfidebonded PMEL species. The 11 luminal cysteine residues within PMEL (Figure 2.8A)
were each individually mutagenized to serine and the single point mutants expressed in
HeLa cells by transient transfection. Like wild-type PMEL, all mutants were able to exit
the ER and localize to a subset of late endosomes and lysosomes labeled with LAMP1 by
immunofluorescence microscopy (Figure 2.9). The mutants were also all appropriately
cleaved in post-Golgi compartments by a proprotein convertase since every one produced
Mβ fragments when analyzed by reducing SDS-PAGE followed by immunoblotting with
αPMEL-C (Figure 2.8B). These data indicate that no single disulfide bond is necessary
for PMEL to pass ER quality control checkpoints or to be appropriately modified by
Golgi enzymes and proprotein convertase. To assess p250 and p160 formation, lysates
were then fractionated by non-reducing SDS-PAGE and immunoblotted with HMB45
(Figure 2.8C-E). Of the four cysteine residues within the region of PMEL that
corresponds to Mα, individual mutations in three of them had little to no effect on p250
and p160. Mutagenesis of C60 resulted in disulfide-bonded PMEL species that were
undistinguishable from those produced by wild-type PMEL (Figure 2.8C, lane 2), and
mutagenesis of C130 or C138 produced only slight increases in the Mr of p250 and p160
(Figure 2.8C, lanes 3-4). This suggests that although C130 and C138 likely participate in
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Figure 2.8

p250 has a C301-dependent intermoelcular disulfide bond and p160 has a C301dependent intramolecular disulfide bond. (A) Schematic from Figure 2.1A showing
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luminal cysteine residues labeled with their amino acid numbers. (B-E) Lysates from
transiently transfected HeLa cells expressing wild-type PMEL, indicated cysteine-toserine mutants of PMEL, or the ΔCS variant were analyzed by reducing (R) SDS-PAGE
and immunoblotted with αPMEL-C (B) or by non-reducing (NR) SDS-PAGE and
immunoblotted with HMB45 (C-E). Single point mutants are analyzed in B, C, and E;
double and triple mutants are analyzed in D together with ΔCS. Positions of molecular
weight standards are indicated to the right of each blot, and relevant PMEL bands are
indicated with arrows.
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Figure 2.9

PMEL cysteine mutants mutants traffic appropriately to late endosomal
compartments when expressed in HeLa cells. HeLa cells transiently transfected with
wild-type PMEL (A-C), PMEL C60S (D-F), PMEL C130S (G-I), C138S (J-L), C301S
(M-O), C475S (P-R), C516S (S-U), C525S (V-X), C533S (Y-AA), C541S (AB-AD),
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C550S (AE-AG), or C566S (AH-AJ) were fixed, labeled with antibodies to PMEL (NKIbeteb, red; A, D, G, J, M, P, S, V, Y, AB, AE, AH) and LAMP1 (H4A3, green; B, E, H,
K, N, Q, T, W, Z, AC, AF, AI), and analyzed by deconvolution immunoflourescence
microscopy. Shown are representative images of each label separately and merged
together (C, F, I, L, O, R, U, X, AA, AD, AG, AJ). Insets show 4X magnifications of the
boxed regions. Scale bar represents 10 µm.
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an intramolecular disulfide bond, neither C60, C130, nor C138 is critical for maintaining
the integrity of p250 or p160. By contrast, mutagenesis of C301 ablated formation of both
p250 and p160, causing most mature PMEL to migrate as free Mα by non-reducing SDSPAGE (Figure 2.8C, lane 5). Since C301 was the only cysteine residue within the Mα
region of PMEL required to stabilize both disulfide-bonded PMEL species, C301 must
participate in a disulfide bond with a cysteine residue in the Mβ region of PMEL to
generate p250 and p160.
In order to generate p250, a disulfide bond must connect the two PMEL monomers
within the dimer. Because p250 contains both Mα and Mβ products of proprotein
convertase cleavage (Figure 2.4), a disulfide bond must also form a bridge between the
Mα and Mβ fragments. If C301 is the only cysteine residue in the Mα region of PMEL
that actively functions to fulfill both of these requirements, then C301 of one PMEL
molecule must form an intermolecular disulfide bond with the Mβ region of the other
PMEL molecule within the p250 dimer. Alternatively, the other cysteine residues in the
Mα region of PMEL could participate in a disulfide bond with Mβ in a redundant manner
such that mutagenesis of any one is insufficient to disrupt disulfide bond formation. We
therefore tested whether combined mutagenesis of the other Mα cysteine residues
impacted p250 or p160 formation. Relative to single point mutations in C130 or C138,
simultaneous mutation of two (C130 and C138) or all three (C60, C130, and C138) of
these cysteine residues had no additional impact on the migration or the formation of
p250 (Figure 2.8D, lanes 2-3). Therefore, C301 must participate in cross-subunit
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disulfide bonds that both (a) link the two PMEL monomers present within the p250 dimer
and (b) link Mα to Mβ within p250.
To generate p160, a disulfide bond must connect C301 of Mα to a cysteine residue of Mβ
in the cleaved version of this species. However, this disulfide bond could form between
Mα and Mβ fragments derived from the same PMEL molecule or from different PMEL
molecules. To distinguish between these possibilities, we analyzed a mutated form of
PMEL lacking the proprotein convertase cleavage site (ΔCS; (82)) by non-reducing SDSPAGE. As predicted by the migration of uncleaved P2 in the “larger” form of p160 by
2D-PAGE (Figure 2.4), the ΔCS variant generates both p250 and p160 with only small
shifts in migration (Figure 2.8D, lane 4). Thus, p160 must contain a disulfide bond that
connects Mα and Mβ regions originating from the same PMEL molecule. Given that
C301 is required for the formation of both the interchain disulfide bond in p250 and the
intrachain disulfide bond in the uncleaved version of p160, a disulfide bond exchange
must occur during the maturation of p250 to p160.
In an attempt to identify the cysteine residue within the Mβ region of PMEL that forms a
disulfide bond with C301, the 7 cysteine residues in this region were individually
mutagenized to serine and the single point mutants analyzed for their effects on the
stability and migration of p250 and p160 by non-reducing SDS-PAGE. Mutagenesis of
C475 resulted in disulfide-bonded PMEL species undistinguishable from those produced
by wild-type PMEL, but mutagenesis of any one cysteine residue within the cysteine-rich
KLD (C516, C525, C533, C541, C550, or C566) completely ablated formation of p160
without disrupting that of p250 (Figure 2.8E). Although these data fail to isolate which
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cysteine residue within the Mβ region of PMEL participates in the disulfide bond with
C301, they suggest that an intact KLD is critical for the formation of p160.

Stabilization of p250 impairs amyloid fibril formation
The ability of KLD cysteine mutants to preferentially stabilize p250 provides a useful
tool with which to investigate the function of this disulfide-bonded PMEL intermediate.
Previous studies have shown that, when overexpressed in non-pigmented cells such as
HeLa or Mel220, PMEL forms melanosome-like fibrillar structures within multivesicular
endosomes that can be visualized and distinguished from non-fibrillar aggregates by
electron microscopy (73,82,141,142). In our experiments, transient expression of wildtype PMEL led to the formation of fibrillar sheets in 36 ± 4.6% (mean ± SEM) of the
multivesicular bodies present within a given HeLa cell (Figure 2.10). However,
following comparable expression of the C566S PMEL mutant – which forms p250 but
not p160 (Figure 2.8E, lane 8) – many fewer multivesicular bodies (18 ± 3.5%; p < 0.01)
showed evidence of fibril formation (Figure 2.10). This result suggests that stabilization
of p250 can impair the formation of functional amyloid fibrils and that resolution of this
disulfide-bonded intermediate may be necessary for fibril formation to ensue.
Surprisingly, expression of the C301S variant – which fails to form both p250 and p160
(Figure 2.8C, lane 5) – resulted in levels of fibril formation (34 ± 3.8% of multivesicular
bodies) that were not significantly different from wild-type PMEL (Figure 2.10). This
could have been interpreted to suggest that p250 and p160 are not required for fibril
formation. However, given that p250 and p160 were detected as distinct entities under
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Figure 2.10

Cells expressing the C566S PMEL mutant exhibit decreased fibril formation while
those expressing C301S PMEL appear similar to wild-type. HeLa cells transiently
transfected with wild-type PMEL, the C301S mutant, or the C566S mutant were analyzed
by transmission electron microscopy. (A) An example of a multivesicular body with
intraluminal vesicles (arrowheads). (B) An example of a multivesicular body with fibrils,
intraluminal vesicles (arrowheads), and a small multilamellar structure commonly found
in late endosomes and lysosomes (asterisk). (C) Fibril-containing organelles and
multivesicular bodies without any evidence of fibril formation were quantified in at least
one field of view per cell, and the percentage of fibril-containing multivesicular bodies
calculated for each cell. Box plots show the combined results of three experiments with
the line in the center representing the median, the box representing the 25th and 75th
percentiles, and the whiskers denoting the minimum and maximum values. Statistics
were performed using a two-tailed unpaired t-test comparing each mutant to wild-type
PMEL. Scale bars are 500 nm.
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non-denaturing conditions by sedimentation and size exclusion chromatography analyses
(Figures 2.2, 2.3), we considered the possibility that similar complexes might form noncovalently in the absence of C301. Indeed, co-immunoprecipitation analyses show that
Mα and Mβ remain associated in cells expressing the C301S mutant of PMEL (Figure
2.11A-B). Moreover, when transfected HeLa cells were analyzed by size exclusion
chromatography, the C301S mutant generates PMEL complexes that have elution
volumes identical to those of wild-type PMEL (Figure 2.11C-H). Thus, while C301dependent disulfide bonds may provide additional stability to p250 and p160, the data
suggest that formation of the corresponding non-covalent complexes is sufficient for
function.

DISCUSSION
Very little is known about the regulation of functional amyloid formation, especially in
mammalian systems. Here we show that the pigment cell-specific amyloid protein PMEL
forms a disulfide-bonded dimer in the ER or early Golgi. Resolution of this dimer to a
disulfide-bonded monomer requires an intact KLD, and inhibiting this process interferes
with the assembly of functional amyloid fibrils. Our data are consistent with a model in
which formation of a disulfide bond-stabilized PMEL dimer in the ER or early Golgi
functions to prevent premature fibril formation early in the secretory pathway (Figure
2.12). The dimer must then be resolved to monomeric forms by disulfide bond
rearrangements in the late Golgi or in a post-Golgi compartment in order to be
incorporated into growing amyloid fibrils.
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Figure 2.11
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Non-covalent complexes with properties similar to p250 and p160 persist despite
C301 mutagenesis. (A, B) Detergent-soluble lysates prepared from transiently
transfected HeLa cells expressing wild-type PMEL (lanes 1-3) or PMEL C301S (lanes 46) were immunoprecipitated using αPMEL-C to the Mβ fragment (C; panel A, lanes 3
and 6), NKI-beteb to the Mα fragment (N; panel B, lanes 3 and 6) or matched negative (-)
controls (normal rabbit serum in panel A, lanes 2 and 5, or the irrelevant monoclonal
antibody OKT4 in panel B, lanes 2 and 5). The immunoprecipitated material and 3% of
the inputs (I; lanes 1 and 4) were analyzed by reducing SDS-PAGE and immunoblotted
with antibodies to the opposite fragment – HMB45 to Mα (panel A) or αPMEL-C to Mβ
(panel B). The migration of molecular weight standards are shown to the right; bands
corresponding to P2, Mα, P1, and Mβ are indicated with arrows. (C-F) HeLa cells
transfected with wild-type PMEL (C, E) or the C301S PMEL variant (D, F) were lysed in
250 mM n-octylglucoside lysis buffer and the detergent extract fractionated by size
exclusion chromatography in 25 mM n-octylglucoside running buffer. Eluted fractions
were analyzed by SDS-PAGE under non-reducing (C, D) or reducing (E, F) conditions
and immuoblotted using the antibodies indicated. The migration of molecular weight
standards is indicated to the right of each blot, and bands corresponding to p250, p160,
Mα, and Mβ are indicated by arrows. Lanes are labeled with fraction numbers as in
Figure 2.3A. (G-H) HMB45 and αPMEL-C immunoreactivity were quantified to
determine the amount of Mα (G) and Mβ (H) present in each fraction. The lowest value
quantified for each species was set to 0% and the highest value was set to 100% for each
experiment. Data represent the mean ± SD of three independent experiments.
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Figure 2.12

Model of PMEL fibril formation. Schematic diagram showing maturation of p250 into
functional amyloid fibrils. The p250 PMEL dimer is resolved to p160 via disulfide bond
rearrangement with proprotein convertase cleavage occuring before, during, or after this
process. The p160 monomers then mature to form the soluble PMEL species Mα+Mβ’
and Mα. These are further cleaved by cysteine proteases into smaller fragments that
assemble into functional amyloid fibrils along with Mα. For simplicity, only one subunit
of the original dimer is shown after p160. Red lines represent disulfide bonds between
C301 and the KLD.
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The discovery of higher molecular weight disulfide-bonded p250 and p160 PMEL
species that react with an antibody known to detect mature – but not immature – PMEL
isoforms originally suggested to us that Golgi-modified forms of PMEL might be
covalently bound to one or more unidentified partner proteins. However, several
observations led us to conclude that these species contain only PMEL. First, p250 and
p160 were detected in both melanocytic cells and transfected HeLa cells. Since pigment
cell-specific proteins are not expressed in HeLa cells, this eliminated the possibility of
covalent association with a pigment cell-specific binding partner. Second, no
polypeptides other than PMEL-derived P2, Mα, and Mβ were consistently detected as
components of p250 or p160 by 2D-PAGE of PMEL immunoprecipitated from cells
metabolically labeled with

35

S-methionine/cysteine for an extended period of time. This

was surprising given that the hypothesized binding partners were expected to be
stoichiometrically represented within the disulfide-bonded PMEL complexes. Third, no
candidate binding partners of the appropriate molecular weight, relative abundance to
PMEL, and subcellular localization were identified by mass spectrometry analysis of
trypsin- or AspN-digested p250 and p160 bands (see Table 2.2 and Supplemental Table
S1). Several ER chaperones were detected in moderate abundance; however, these are
common contaminants of protein purification by affinity chromatography, and detailed
analyses of two abundant protein disulfide isomerase family members revealed
interactions with immature ER forms of PMEL but not p250 or p160 (data not shown).
The mass spectrometry data effectively rule out the possibility that a stoichiometric
constituent of p250 or p160 was missed by 2D-PAGE due to poor labeling with

35

S-

methionine/cysteine. Thus, while it remains remotely possible that a poorly radiolabeled,
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ubiquitous binding partner might fail to generate peptides detectable by mass
spectrometry using either of two proteases, we favor the more likely interpretation that
p250 and p160 are comprised entirely of PMEL.
With a molecular weight approximately twice that of a PMEL monomer, p250 is most
likely a PMEL dimer. The exact composition of p160, however, was less obvious at first.
The migration of p160 by non-reducing SDS-PAGE is considerably slower than that of a
completely reduced, Golgi-modified PMEL monomer. We initially interpreted this to
suggest that p160 is comprised of a full-length PMEL monomer – or linked Mα/Mβ
cleavage products – in complex with an additional PMEL fragment such as Mβ.
However, the migration of p160 by non-reducing SDS-PAGE was only minimally altered
in the absence of Mβ production as tested using the proprotein convertase cleavage site
mutant ΔCS. In addition, the naturally occurring p160 comprised of uncleaved, fulllength, Golgi-modified P2 contained no additional PMEL fragments when analyzed by
2D-PAGE. As such, we interpret the data to indicate that P2 migrates with a Mr of
~160,000 when constrained by disulfide bonds but a Mr of ~120,000 when fully reduced.
We speculate that the disulfide-bonded structure of p160 limits accessibility to SDS, thus
reducing the migration of this species by non-reducing SDS-PAGE.
Our results are consistent with a model in which the p250 dimer is an obligate precursor
of the p160 monomer since (i) the formation of p250 occurs prior to that of p160 by
metabolic pulse/chase analysis, (ii) inhibition of intra-Golgi transport in cells treated with
monensin leads to the accumulation of p250 and depletion of p160, and (iii) none of the
cysteine mutants produce p160 independently of p250. Complicating this interpretation,
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however, is the finding that both p250 and p160 contain the full-length Golgi-modified
P2 form of PMEL and the Mα/Mβ form cleaved by proprotein convertase when analyzed
by 2D-PAGE. Since Mα and Mβ are generated by proprotein convertase cleavage of P2
in the TGN (73) or endosomes (74), ideally p250 would contain only uncleaved P2 and
p160 would contain only cleaved Mα/Mβ. While these data raise the possibility that p250
represents an independent “dead-end” pathway for PMEL that never generates fibrils, we
consider it more likely that p250 is converted to p160 at the same intracellular site but
independently of proprotein convertase cleavage such that cleavage can occur before,
during, or after resolution of the p250 dimer (Figure 2.12).
Our data further suggest that a disulfide bond rearrangement is required to convert p250
to p160. This is because C301 – a cysteine residue conserved throughout vertebrate
evolution (88) – participates in a cross-subunit disulfide bond between two different
PMEL molecules within p250 but in a disulfide bond between Mα and Mβ derived from
the same PMEL precursor within p160. Although proprotein convertase cleavage of both
monomers within the p250 dimer would immediately resolve p250 into a “monomeric”
form in which Mα derived from one protomer is linked to Mβ from the other protomer,
the observation that p160 can form without proprotein convertase cleavage suggests that
the cross-subunit disulfide bond of p250 is broken to form a new disulfide bond
connecting Mα and Mβ derived from the same PMEL protomer. While disulfide bonds
are typically formed and remodeled in the ER (143), disulfide bond rearrangements
outside the ER have been reported (131,144). Interestingly, if our model is correct, the
disulfide exchange likely occurs without the enzymatic activity of a protein disulfide
isomerase; typical ER protein disulfide isomerases such as PDIA1 and PDIA3 associate
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exclusively with ER forms of PMEL (T. Ho, unpublished data), and melanocytes do not
express the only known protein disulfide isomerase of the endocytic pathway, GILT (γinterferon inducible lysosomal thiol reductase) (145), unless they are stimulated with γinterferon ((146) and M. Marks, unpublished data). In addition, failure to treat cells with
fresh NEM prior to lysis resulted in poor preservation of the disulfide-bonded PMEL
species (T. Ho, unpublished data), suggesting that nearby cysteine residues rapidly reduce
p250 and p160 when not blocked by alkylation. Since the integrity of the PMEL KLD is
required for the resolution of p250 to p160, we speculate that cysteine residues within the
KLD initiate this disulfide exchange in an autocatalytic manner. Assessment of this
model would require the purification of properly folded recombinant PMEL isoforms,
which are not currently available.
Many layers of regulation must exist to protect organisms against the dire consequences
of inappropriate amyloid formation. Our data indicate that the KLD domain protects
against premature PMEL fibril formation by regulating the resolution of a disulfidestabilized PMEL dimer. The importance of an intact KLD is supported by the finding that
fibril formation is impaired in HeLa cells expressing the C566S mutant, a variant of
PMEL that generates p250 dimers but not p160 monomers. Given that mutagenesis of
any single cysteine residue within the KLD – and even a small deletion (B. Watt,
unpublished data) – results in the same biochemical effect on p250 and p160, we predict
that any disruption to the cysteine arrangement within the KLD will interfere with fibril
formation. Surprisingly, all of the individual cysteine mutants pass quality control
checkpoints in the ER, are cleaved by proprotein convertases in the TGN or endosomes,
and localize appropriately to late endosomes and lysosomes. This suggests that the KLD
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acts primarily in a post-Golgi compartment to regulate p160 formation and promote the
assembly of functional amyloid fibrils. Whether the KLD can promote fibril formation
independent of its effect on the disulfide-bonded PMEL species cannot be determined
with the present data, but the progressive disulfide bond changes during PMEL
maturation suggest that a primary function of the KLD is to regulate these changes.
Intriguingly, mutagenesis of C301 – the only cysteine residue integral to the formation of
both p250 and p160 – does not impair PMEL fibril formation. As shown by size
exclusion chromatography, this is most likely because the C301S PMEL variant forms
non-covalent complexes similar to the disulfide-bonded species formed by wild-type
PMEL. This indicates that C301-dependent disulfide bonds are not required for amyloid
fibril formation but rather stabilize energetically favorable conformations at distinct
stages of the PMEL biosynthetic pathway. We speculate that loss of this additional
stability under physiological expression conditions might lead to premature fibril
formation and consequent pathology that is not detectable in the short-term assays used
here, as has been observed for several dominant PMEL mutants (147).
PMEL is not the only amyloid protein influenced by disulfide bonds. Reduction of the
single disulfide bond in the functional amyloid protein somatostatin-14 in vitro results in
fibrils that form faster, are more resistant to denaturation, and have decreased monomer
release (148). Reduction of the intrachain and/or one of two interchain disulfide bonds in
porcine insulin also accelerates fibril formation (149). Interestingly, the cysteine residues
of tau can participate in intramolecular or intermolecular disulfide bonds; the
intramolecular disulfide bonds retard fibril formation by restricting the protein to
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conformations incompatible with the amyloid fold, whereas the intermolecular disulfide
bonds accelerate amyloid fibril formation (150). However, many proteins including
insulin have the ability to form amyloid aggregates in vitro but do not typically do so in
vivo (151). Since many proteins of the secretory pathway contain disulfide bonds, we
suggest that the use of disulfide bonds to stabilize pro- or anti-amyloidogenic folding
intermediates might be a common mode of regulation for amyloid proteins within the
endomembrane system.
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ABSTRACT
Mutations in the proton-dependent sucrose transporter SLC45A2 lead to a disorder
known as oculocutaneous albinism type 4 (OCA4). Here, we show that HA-tagged
human SLC45A2 localizes to punctate structures on or near the limiting membrane of
melanosomes in a process that requires an intact tyrosine-based sorting motif located
within a cytoplasmic loop of the transporter. Mutagenesis of the critical tyrosine residue
within this sorting motif leads to mislocalization of HA-SLC45A2 to the plasma
membrane and decreased pigmentation suggesting that SLC45A2 functions most
effectively when present on or near melanosomes. Preliminary data also indicate that
SLC45A2-deficient melan-uw1 mouse melanocytes accumulate hypopigmented mature
melanosomes and that SLC45A2 may be required to maintain the neutral pH of late-stage
melanosomes in order to achieve efficient melanin biosynthesis.
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INTRODUCTION
Oculocutaneous albinism (OCA) is a group of autosomal recessive disorders
characterized by hypopigmentation of the hair, skin, and eye. To date, seven types of
non-syndromic oculocutaneous albinism have been identified, each resulting from
mutation in a different gene associated with melanin production. OCA1 is caused by
mutations in tyrosinase (TYR) (152), the rate-limiting enzyme in the synthesis of both
eumelanins and pheomelanins. OCA2 is caused by mutations in the pink-eyed dilution
protein (also known as the P protein or simply OCA2) (153), which is a chlorideselective ion channel that neutralizes the pH of maturing melanosomes (154). OCA3
results from mutations in tyrosinase related protein 1 (TYRP1) (155) which directly or
indirectly facilitates the conversion of DHICA to eumelanin (102), and OCA4 results
from mutations in SLC45A2 (15), a proton-dependent sucrose symporter (103). OCA5 is
caused by mutations in an unidentified gene located on chromosome 4 (4q24) (104),
OCA6 is caused by mutations in SLC24A5 (11), a putative potassium-dependent
sodium/calcium exchanger, and OCA7 is caused by mutations in the uncharacterized
orphan gene C10orf11 (105).
Despite the different underlying mutations, patients with OCA2 and OCA4 are clinically
indistinguishable and must be characterized by molecular genetic testing. While all
patients with oculocutaneous albinism present with hypopigmented skin and hair and
some degree of ocular defects including reduced retinal pigment and foveal hypoplasia
leading to poor visual acuity, those with OCA1 are usually the most severely affected
(94). Patients with OCA1 tend to have hair that is completely white and the worst vision,
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whereas patients with OCA3 typically have the least severe disease, red hair, and reddish
skin due to an increased ratio of pheomelanin to eumelanin. In contrast, patients with
OCA2 and OCA4 have decreased production of both eumelanin and pheomelanin with
light pigmentation of the hair and skin. OCA5, OCA6, and OCA7 have only recently
been identified, and the range of clinical phenotypes exhibited by these patients has yet to
be thoroughly characterized (156). Analyses of hair from mouse models of OCA2 and
OCA4 are also much more similar to one another than to the other mouse models of
oculocutaneous albinism, suggesting that the function of SLC45A2 may be related to that
of OCA2 in the melanosome (Table 3.1).
OCA2 increases melanosomal pH to optimize the activity of the enzyme TYR, which
functions best at pH 6.8 (7,100). Ectopic expression of the chloride channel in nonpigment cells causes endolysosomal pH to rise (154), likely by facilitating the export of
H+ as well as Cl-. Consistent with a similar function in melanocytes, inhibition of the
vacuolar-type H+-ATPase (V-ATPase) by bafilomycin A1 restores pigmentation in
OCA2-deficient melanocytes (101). Though far less is known about SLC45A2, all
available evidence suggests that this H+-sucrose symporter regulates melanosomal pH
through an independent mechanism. Knockdown of a catalytic subunit of the V-ATPase
complex in SLC45A2-deficient zebrafish larvae or overnight treatment of SLC45A2deficient zebrafish embryos with bafilomycin A1 increases melanin production,
suggesting that SLC45A2, like OCA2, helps to neutralize the pH of melanosomes (119).
However, SLC45A2 and OCA2 appear to regulate melanosomal pH independently. Mice
carrying mutations in both SLC45A2 and OCA2 are more severely hypopigmented than
mice carrying only one of the two mutations (157). In addition, primary mouse
80

	
  
Table 3.1

Mouse
C57BL-a/a, black
B10-a/a, black
B10-c/c, albino
B10-p/p, pink-eyed
B10-b/b, brown
C57BL-uw/uw,
underwhite
C57BL-uwd/uwd,
underwhite
C57BL-Uwdbr/Uwdbr,
underwhite

Corresponding
Human Disorder
----OCA1
OCA2
OCA3

PTCA
(ng/mg)
1590
1560
2
70
459

Total AHP
(ng/mg)
49
43
18
91
89

Reference

OCA4

29

80

(157)

OCA4

89

108

(157)

OCA4

85

114

(157)

(158)
(159)
(159)
(159)
(159)

Eumelanin (PTCA) and pheomelanin (AHP) content of mouse hair. Adapted from:
Quantitative Analysis of Eumelanin and Pheomelanin in Humans, Mice, and Other
Animals: a Comparative Review (160).
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melanocytes from underwhite (uw) mice with a nonsense mutation in SLC45A2 secrete
dark vesicles containing tyrosinase, TYRP1, and DOPAchrome tautomerase (DCT) that
are easily pelleted by centrifugation (118) while melanins present in the media of cells
lacking OCA2 are not easily pelleted by centrifugation at 12,000g (161).
To better understand how SLC45A2 contributes to melanosome biogenesis, we studied
the subcellular localization of ectopically expressed SLC45A2. Our results show that
SLC45A2 localizes to melanosomes, concentrating in punctate structures in or near the
melanosomal membrane, and that mutagenesis of the critical tyrosine residue within a
tyrosine-based signaling motif of SLC45A2 causes mislocalization to the plasma
membrane and a consequent decrease in pigmentation. Preliminary data also suggest that
SLC45A2 maintains the elevated pH of mature melanosomes and that overexpression of
OCA2 can compensate for defects in SLC45A2.

RESULTS
Wild-type SLC45A2 localizes to punctate structures associated with melanosomes
Since antibodies that recognize endogenous SLC45A2 are not suitable for
immunofluorescence microscopy, we studied the localization of SLC45A2 using a
functional HA-tagged version of the protein. To determine whether the epitope tag
interfered with SLC45A2 activity, we tested the ability of human HA-SLC45A2 to rescue
pigmentation in immortalized melan-uw1 melanocytes derived from the SLC45A2deficient OCA4 mouse model, underwhite. Toward this end, we both transiently
transfected and stably expressed human HA-SLC45A2, a HA-tagged Y268A variant
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(described below), and an unrelated HA-tagged transporter with multiple transmembrane
domains (HA-SLC35D3) and evaluated the degree to which pigmentation was restored in
these cells. The melan-uw1 cells transiently expressing HA-SLC45A2, the Y268A
variant, or the HA-tagged negative control were examined 48 or 72 h after transfection,
and the number of transfected melanocytes that were unpigmented (Figure 3.1A),
partially pigmented (Figure 3.1B), or fully pigmented (Figure 3.1C) quantified by
bright-field microscopy. At 48 h, 69 ± 3.4% (mean ± SD) of the melanocytes transfected
with HA-SLC45A2 exhibited some degree of pigmentation, with about half the cells
pigmented at levels comparable to immortalized wild-type melanocytes derived from
C57BL/6 mice (melan-Ink4a) and half more modestly pigmented (Figure 3.1D). At 72 h,
79 ± 7.3% exhibited some degree of pigmentation, again with approximately half fully
pigmented and half partially pigmented (Figure 3.1E). In contrast, very few cells
transiently expressing the HA-SLC35D3 negative control showed evidence of
pigmentation. Restoration of pigment in melan-uw1 cells stably expressing HASLC45A2, the Y268A variant, or the HA-tagged SLC35D3 negative control was
evaluated by measuring the amount of melanin per mg of detergent-soluble lysate.
Consistent with our results by bright-field microscopy, the melan-uw1 melanocytes
stably expressing human HA-SLC45A2 had 3-fold more melanin than melanocytes stably
expressing HA-SLC35D3 in this assay (Figure 3.2). Together, these data indicate that
human HA-SLC45A2 is functional in melan-uw1 mouse melanocytes and that the
behavior of this epitope-tagged human construct will likely reflect that of the endogenous
mouse protein.
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Figure 3.1

HA-SLC45A2 restores pigmentation to hypopigmented underwhite melanocytes.
Immortalized SLC45A2-deficient underwhite melanocytes (melan-uw1) transiently
expressing human HA-SLC45A2, the Y268A variant of HA-SLC45A2 (Y268A), or HASLC35D3 as a negative control (Neg. Control) were categorized as unpigmented (A),
partially pigmented (B), or fully pigmented (C) by A. Lefkovith and the percentage of
cells in each category analyzed 48 h (D) or 72 h (E) after transfection. Shown is the mean
± SD of three independent experiments in which at least 10 cells were evaluated for each
transfected cell type. Scale bars represent 10 µm.
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Figure 3.2

Restoration of pigment is also observed in stable cell lines expressing HA-SLC45A2
and related variants. The amount of melanin per mg protein in melan-uw1 cell lines
stably expressing human HA-SLC45A2, the Y268A variant of HA-SLC45A2, or HASLC35D3 as a negative control (Neg. Control) was analyzed by K. Haltaufderhyde.
Shown is the mean ± SD of four independent experiments.
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While rudimentary studies of SLC45A2 localization in MNT-1 cells (117) and primary
human melanocytes (116) have been reported, the subcellular localization of SLC45A2
has yet to be characterized in detail. Therefore, to thoroughly and accurately define the
subcellular localization of SLC45A2, we expressed our HA-tagged construct transiently
or stably in wild-type mouse melanocytes and analyzed the cells by immunofluorescence
microscopy. Following transient transfection, the epitope-tagged protein was observed in
rings surrounding pigment granules as is commonly observed for proteins of the
melanosome limiting membrane (Figure 3.3). Also consistent with localization to
melanosomes, HA-SLC45A2 staining overlapped with that of TYR and TYRP1 but not
LAMP2 (Figure 3.4). Interestingly, careful examination of some of these images showed
that HA-SLC45A2 frequently clustered in punctate spots within the rings surrounding
pigment granules and/or the melanosomal marker proteins TYR or TYRP1. This pattern
of localization was even more pronounced in melan-uw1 melanocytes stably expressing
HA-SLC45A2 with the epitope-tagged protein localizing primarily to bright puncta
adjacent to pigment granules or within rings labeled by antibodies to TYR or TYRP1
(Figure 3.5). These data suggest that SLC45A2 localizes to a distinct domain in the
melanosomal membrane or to small vesicles closely associated with melanosomes when
expressed at modest levels. More uniform labeling of the entire melanosome limiting
membrane frequently observed in transiently transfected cells likely reflects an artifact of
overexpression.
Melanosomal proteins often localize to late endosomes and lysosomes when expressed in
non-pigment cells. To test whether the same is true for SLC45A2, we transiently
expressed the HA-tagged construct in HeLa cells and evaluated the subcellular
86

	
  
Figure 3.3

HA-SLC45A2 localizes to rings surrounding pigment granules when transiently
overexpressed in wild-type melanocytes. Immortalized melan-Ink4a melanocytes
transiently expressing HA-SLC45A2 (A) or HA-SLC35D3 as a negative control (B) were
fixed 2 d after transfection, labeled with an antibody to the HA tag, and analyzed by A.
Lefkovith using bright field and deconvolution immunofluorescence microscopy. Shown
are representative bright field and deconvolution immunoflourescence images separately
and merged together. Pigment granules have been pseudocolored blue in the merged
image. Insets show 8.25x magnifications of the boxed regions. Scale bars represent 10
µm.
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Figure 3.4

HA-SLC45A2 colocalizes with melanosomal membrane proteins in wild-type
melanocytes. (A, B, C) Immortalized melan-Ink4a melanocytes transiently expressing
HA-SLC45A2 were fixed 2 d after transfection, labeled with antibodies against TYRP1
(TA99; A), TYR (αPEP7h; B), or LAMP2 (GL2A7; C) and the HA tag, and analyzed by
A. Lefkovith using bright field and deconvolution immunofluorescence microscopy. (D)
Melan-Ink4a melanocytes stably expressing HA-SLC45A2 were also fixed, stained with
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antibodies to TYRP1 (TA99) and the HA tag, and analyzed by T. Ho using bright field
and deconvolution immunofluorescence microscopy. Shown are representative images of
each label separately and merged together. Insets show 8.25x magnifications of the boxed
regions. Scale bars represent 10 µm.
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Figure 3.5

HA-SLC45A2 concentrates in puncta on or near melanosomes when stably
expressed

in

SLC45A2-deficient

melan-uw1

cells.

Immortalized

melan-uw1

melanocytes stably rescued with HA-SLC45A2 were fixed, labeled with antibodies
against TYRP1 (TA99; A), TYR (αPEP7h; B), or LAMP2 (C) and the HA tag, and
analyzed by T. Ho using bright field and deconvolution immunofluorescence microscopy.
Shown are representative images of each label separately and merged together. Insets
show 8.25x magnifications of the boxed regions. Scale bars represent 10 µm.
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localization of HA-SLC45A2 by immunofluorescence microscopy. As shown in Figure
3.6, punctate clusters of HA-SLC45A2 were observed near or within the limiting
membrane of late endosomes and lysosomes labeled with LAMP1 suggesting that
pigment cell-specific proteins are not required for the localization of HA-SLC45A2 to
these domains.

SLC45A2 localization to melanosomes requires a tyrosine-based signal (Yxxϕ)
Melanosome maturation involves the sequential delivery of melanosomal cargo to
precursor organelles. TYR, TYRP1, and OCA2 contain acidic dileucine-based sorting
signals that interact with AP-1 and/or AP-3 in the cytoplasm to deliver these proteins to
melanosomes (14,107,162). Examination of the primary sequence of SLC45A2 reveals
no dileucine-based motif within any of the predicted cytoplasmic domains of SLC45A2.
However, between the 6th and 7th transmembrane domains of SLC45A2 lies a predicted
AP-binding tyrosine-based motif (Yxxϕ) starting with Y268. This motif is conserved in
vertebrates – all of which have specialized pigmented cells – but not in invertebrates,
plants, or yeast which either lack pigment cells or harbor distinct classes of pigments
(Figure 3.7). Since these more distant homologs of SLC45A2 are thought to function at
the plasma membrane, this pattern of evolutionary conservation suggests that the
melanosomal localization of human SLC45A2 could be mediated by the tyrosine-based
motif between the 6th and 7th transmembrane domain.
To test this hypothesis, we developed a Y268A variant of SLC45A2 that disrupts the
tyrosine-based motif. When expressed in wild-type melanocytes, this variant is expressed
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Figure 3.6

HA-SLC45A2 concentrates in puncta on or near late endosomes and lysosomes
when expressed in non-pigment HeLa cells. HeLa cells transiently expressing HASLC45A2 were fixed 2 d after transfection, labeled with antibodies to the HA tag (green)
and

LAMP1

(H4A3,

red),

and

analyzed

by

T.

Ho

using

deconvolution

immunoflourescence microscopy. Shown are representative images of each label
separately and merged together. Insets show 8x magnifications of the boxed regions.
Scale bar is 10 µm.
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Figure 3.7
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LSE-QAIKKELKKKN--NTIYYIQETTQLELQMASDDPKRLEALQGSYQNGYSPAVEKQ
-----------------GEIFEF-----------------------------------APLLDDLQSKGLEHSKLNNG---------------------TANGIKYERVERDTDEQF

285
285
296
313
357
258
332

The tyrosine-based motif of SLC45A2 is conserved in vertebrates but not in lower
organisms. Amino acid sequence comparison was performed on SLC45A2 orthologs in
the species indicated using COBALT Constraint-based Multiple Protein Alignment Tool
(163). Shown is the region surrounding the SLC45A2 tyrosine-based motif located in the
cytoplasmic loop between the 6th and 7th transmembrane domains. Highlighted in red is
the conserved Yxxϕ tyrosine-based motif. The GenBank accession numbers from which
the sequences are derived are as follows: Homo sapiens SLC45A2 [Q9UMX9.2], Mus
musculus SLC45A2, [P58355.1], Gallus gallus SLC45A2 [ABK51634.1], Danio rerio
SLC45A2 [AAI54628.1], Drosophila melanogaster SLC45A2 ortholog 1, isoform A
[NP_648292.1], Schizosaccharomyces pombe SUT1 [CAB16264.1], Arabidopsis
thaliana SUC3 [O80605.1].
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both diffusely throughout the cell – likely on the plasma membrane – and in puncta that
did not colocalize with pigment (Figure 3.8). Consistent with this observation,
expression of the Y268A variant of HA-SLC45A2 in HeLa cells resulted in localization
both throughout the cell and in puncta that did not colocalize with LAMP1 (Figure 3.9).
Preliminary results suggest that the diffuse staining results from accumulation of the
Y268A variant at the plasma membrane with the puncta corresponding to cell surface
projections or early endocytic vesicles; however, further experiments are necessary to
determine whether this variant also localizes to other non-pigmented intracellular
compartments.
Expression of the Y268A variant in melan-uw1 melanocytes partially restored
pigmentation to these cells. When expressed transiently, 46 ± 4.5% of the melanocytes
showed some degree of pigmentation 48 h post-transfection with that number increasing
to 59 ± 8.5% after 72 h (Figure 3.1D-E). This surprisingly high degree of pigmentation is
most likely a consequence of overexpression since melan-uw1 cells stably expressing the
Y268A variant produce approximately half the melanin of melan-uw1 cells stably
expressing wild-type HA-SLC45A2 (Figure 3.2; note that stable cell lines generated
using the retroviral pBMN vector typically have much lower levels of protein expression
compared to cells transiently transfected with multiple copies of pCI-based plasmids).
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Figure 3.8

The conserved tyrosine within a putative Yxxϕ sorting signal is required for
SLC45A2 localization to melanosomes. Wild-type melanocytes transiently expressing
the Y268A variant of human HA-SLC45A2 were fixed 2 d after transfection, labeled
with an antibody to the HA tag, and analyzed by A. Lefkovith using bright field and
deconvolution immunoflourescence microscopy. Shown are representative bright field
and deconvolution immunoflourescence images separately and merged together with
pigment granules pseudocolored blue in the merged image. Insets show 8.25x
magnifications of the boxed regions. Scale bar represents 10 µm.
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Figure 3.9

The conserved tyrosine within a putative Yxxϕ sorting signal is required for
SLC45A2 localization to late endosomes and lysosomes in non-pigment HeLa cells.
HeLa cells transiently expressing the Y268A variant of HA-SLC45A2 were fixed 2 d
after transfection, labeled with antibodies to the HA tag (green) and LAMP1 (H4A3, red),
and analyzed by T. Ho using deconvolution immunoflourescence microscopy. Shown are
representative images of each label separately and merged together with insets showing
8x magnifications of the boxed regions. Scale bar represents 10 µm.
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DISCUSSION
With the discovery and characterization of each gene associated with OCA, we gain new
insights into the molecular mechanisms of melanosome biogenesis and grow one step
closer to potentially developing treatments for OCA patients. OCA4 is caused by
mutations in the proton-dependent sucrose symporter SLC45A2. In this chapter, we show
that a HA-tagged version of human SLC45A2 localizes to and functions at melanosomes.
HA-SLC45A2 clusters in punctate structures on or near the melanosome limiting
membrane in wild-type melanocytes and melan-uw1 melanocytes. The protein also
clusters in puncta on or near the lysosomal limiting membrane in HeLa cells. Preliminary
data suggest that these puncta do not co-localize with RAB38-GFP or syntaxin13-GFP
(Figure A1). Syntaxin13 is a SNARE protein present on early endosomes (164), and
RAB38 is a small G protein that localizes both to tubular domains of early endosomes
and to stage III and IV melanosomes (94). Together with the observation that ectopically
expressed HA-SLC45A2 in non-pigment HeLa cells localizes on/near lysosomes, these
data suggest that the punctate clusters of HA-SLC45A2 most likely reflect an association
with melanosomes and lysosomes – or a subdomain of melanosomes and lysosomes –
and not melanocyte-specific transport intermediates.
The localization of HA-tagged SLC45A2 to melanosomes or lysosomes requires an intact
tyrosine-based signaling motif between the 6th and 7th transmembrane domains of the
protein. Mutagenesis of the critical tyrosine residue within this motif results in
mislocalization of HA-SLC45A2 to the plasma membrane and a decrease in melanin
synthesis suggesting that human SLC45A2 must traffic to melanosomes to efficiently
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produce pigment. The decrease in melanin could also reflect decreased expression of the
Y268A variant in the melan-uw1 stable cell lines in comparison to wild-type HASLC45A2 (Figure A2). However, given that overexpression of the Y268A variant by
transient transfection also impairs pigmentation, we favor the more likely interpretation
that melanosomal localization is required for optimal SLC45A2 function.
What is the function of human SLC45A2 under normal physiological conditions? Since
many more “stalled” stage III melanosomes were observed in a preliminary electron
microscopy experiment comparing melan-uw1 melanocytes with wild-type melanocytes
(Figure A3), we hypothesize that SLC45A2 is needed for the maturation of stage III
melanosomes to stage IV melanosomes. Since knockdown of OCA2 has been shown to
increase the number of stage I and stage II melanosomes without significantly affecting
the number of stage III melanosomes (165), we speculate that OCA2 may initiate the
process of neutralizing melanosomal pH in early stage melanosomes while SLC45A2
maintains it in stage III and stage IV melanosomes. Consistent with this idea, OCA2
appears to localizes predominantly to internal structures within melanosomes and
overlaps to only a minor degree with proteins on the limiting membrane of mature
melanosomes such as TYRP1 (14,166), suggesting that OCA2 might be cleared from the
limiting membrane of stage III melanosomes by invagination onto intraluminal
membranes (88,167,168). The presence of hypopigmented late-stage melanosomes in
melan-uw1 cells is also supported by preliminary immunofluorescence and bright field
microscopy experiments showing co-localization of TYR and TYRP1 – but not PMEL, a
marker of early stage I and stage II melanosomes – with lightly pigmented structures
(Figure A4). The notion that both OCA2 and SLC45A2 increase the pH of melanosomes
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to provide an optimal environment for tyrosinase activity is further supported by another
preliminary experiment in which, surprisingly, transient overexpression of OCA2-HA in
SLC45A2-deficient melan-uw1 mouse melanocytes resulted in complete restoration of
pigment by bright field microscopy (Figure A5).
Together, these experiments suggest that OCA4 is caused by stage III melanosomes that
are too acidic for optimal TYR activity. It remains to be tested whether melan-uw1
mouse melanocytes “rescued” with OCA2-HA are equivalent to those rescued using HASLC45A2 and whether overexpression of SLC45A2 can restore pigmentation in OCA2deficient melan-p1 mouse melanocytes. Why or how HA-SLC45A2 clusters in discrete
puncta on or near the limiting membrane of melanosomes is also unclear and may hinder
attempts to record current flow using patch-clamp techniques. However, we plan to
examine

melan-uw1

mouse

melanocytes

stably

expressing

HA-SLC45A2

by

immunoelectron microscopy and hope that this experiment will provide the resolution
necessary to determine whether the punctate structures we observe by light microscopy
correspond to regions near or within the melanosomal membrane.
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CHAPTER 4
Discussion
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Testing the toxicity of a functional amyloid protein
While pathogenic amyloid proteins have been studied for decades, functional amyloid
proteins are still a relatively recent discovery. In chapter 2, we proposed one mechanism
of regulation for the functional amyloid protein PMEL in which the oligomeric state of
PMEL regulates its propensity for amyloid formation. Our model suggests that disulfidebonded PMEL dimers prevent premature fibril formation in early secretory compartments
but must be resolved prior to functional amyloid assembly in early endosomes/stage I
melanosomes. This process provides an additional layer of regulation to ensure that
PMEL forms amyloid at exactly the right place and time. We speculate that other
functional and pathogenic amyloid proteins might share a similar mechanism of
regulation and that breakdown of this mechanism – at least for PMEL – could lead to
inappropriate and potentially toxic amyloid formation earlier in the secretory pathway.
But would it? Identification of the toxic amyloid species remains a huge area of
controversy within the field of amyloid biology, and the number of questions only
multiplied with the discovery of functional amyloid proteins. Study of these proteins
demonstrated that the final product of amyloid formation was not necessarily toxic.
However, it remains unknown what separates functional amyloid proteins from
pathogenic amyloid proteins. It might simply be a matter of context. For example,
accumulation of the (normally extracellular) bacterial amyloid protein curli inside cells
lacking the chaperone protein CsgC has been shown to increase cell death (46). Would
other functional amyloid proteins also exhibit toxicity if expressed in different tissues
and/or without robust regulation? Would PMEL?
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Two naturally occurring dominant variants of PMEL suggest that the manner in which
PMEL fibril formation occurs is not inconsequential. The Dominant white (DW) and
Silver (HoSi) PMEL alleles form aberrant, tightly packed PMEL fibrils that impair
pigmentation when expressed in melanocytes. Surprisingly, however, the mutations
responsible for the loss of pigment in Dominant white chickens and Silver horses are not
located in amyloid-forming regions of the protein but near the transmembrane domain.
The DW allele involves the insertion of 3 additional amino acids in the PMEL
transmembrane domain (TMinsWAP), while the Silver allele is defined by a single amino
acid mutation in an arginine residue adjacent to the PMEL transmembrane domain
(TMR625C). How exactly these changes affect PMEL fibril formation is not known;
however, their distance from the NTR and PKD domains (which most likely constitute
the core of PMEL amyloid fibrils (86)) suggest that they influence the manner by which
PMEL subunits assemble to form amyloid and/or the structure of the final product.
Moreover, their dramatic effect on chicken plumage and horse hair suggest that changes
in the regulation of PMEL amyloid assembly can radically alter PMEL function.
The C301S PMEL mutant is not a naturally occurring PMEL allele, and therefore, how
the protein affects pigmentation in vivo is not known. However, it would be interesting to
test whether C301S PMEL is toxic given that the non-covalent dimers formed by this
mutant are likely to be less stable than disulfide-bonded p250 dimers. Transient
overexpression of the C301S mutant in non-pigment HeLa cells showed no noticeable
increase in toxicity when compared to the wild-type protein, and there was no obvious
accumulation of C301S amyloid fibrils elsewhere in cells examined by electron
microscopy. However, the DW variant of PMEL also formed normal-appearing amyloid
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fibrils when overexpressed in HeLa cells; closely packed fibrils that inhibit
melaninization were only observed upon expression in mouse melanocytes (147). Thus, it
would be interesting to perform additional studies on the C301S mutant using highpressure freezing to see if fibril formation occurs earlier in the secretory pathway or if
fibril morphology is affected when the mutant protein is expressed at endogenous levels
in mouse melanocytes.
If reduced cell viability and/or premature fibril formation were to be observed in vitro,
we would then express the C301S mutant in vivo, a process we have already begun for
DW PMEL. Because we only achieve low levels of protein expression using stable
transfectants and because long-term effects on cell survival are difficult to assess using
transient expression systems, we are generating transgenic mice that conditionally
express PMEL under the control of the CAG promoter. The targeting construct was
produced by insertion of wild-type PMEL or DW PMEL into the CAG-STOP-eGFPROSA Targeting Vector (Figure A6) and has been electroporated into C57BL/6
embryonic stem (ES) cells. These ES cells have been screened by the Gene Targeting
Core at the University of Pennsylvania using Southern hybridization and by myself using
PCR. These cells currently await injection into mouse blastocysts. One preliminary
experiment suggests that these animals will be worth the wait. When co-transfected with
Cre recombinase and a plasmid containing a puromycin selection cassette by T. Raabe of
the Gene Targeting Core, ES cells expressing DW PMEL have decreased viability in
comparison to control cells transfected with only the puromycin plasmid. In contrast, no
difference in survival was observed for ES cells expressing wild-type PMEL. These data
suggest that the formation of DW amyloid is toxic to ES cells, whereas that of wild-type
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PMEL is not. It will be interesting to see whether this result holds true in primary
melanocytes derived from newborn transgenic mice and treated with Cre recombinase in
vitro, and it will be even more exciting to test whether mice expressing wild-type or DW
PMEL in dopaminergic neurons of the substantia nigra show signs of neurodegeneration.
If this same experiment were to be performed using C301S PMEL, we would predict that
mice carrying the C301S PMEL mutant would exhibit signs of neurodegeneration earlier
than mice expressing wild-type PMEL in their dopaminergic neurons. The phenotype
may also be more severe due to increased neuronal loss caused by amyloid fibrils that
have formed in a different manner, in an earlier location, at the incorrect time, and/or
with different structural properties. However, dopaminergic neurons of C301S mice may
be less damaged than those of mice expressing DW PMEL as the ability to form
noncovalent C301S dimers will likely enable the majority of the protein to undergo
normal, nontoxic amyloid assembly.

The function of the PMEL KLD
PMEL amyloid, like all amyloid, is comprised of fibrils in which the β strands are
organized perpendicular to the long axis of the fibril. Once formed, this hydrogen-bonded
cross-β sheet structure is incredibly stable and highly insoluble, not to mention
potentially toxic. Therefore, the conversion of PMEL from a non-amyloid protein to an
amyloid one is likely to be highly regulated to ensure that the conformational change
occurs quickly and efficiently in early stage melanosomes but not elsewhere in the cell.
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While the function of the PMEL KLD is unknown, an intact KLD is clearly necessary for
efficient fibril formation. Very little of the amyloidogenic Mα fragment is observed free
in solution within MNT-1 cells and virtually none is observed in HeLa cells transiently
expressing wild-type PMEL suggesting that (1) free Mα is rapidly processed into amyloid
fibrils and (2) association with the KLD in p250, p160, and Mα+Mβ’ species may
antagonize adoption of the amyloid fold. Our results additionally indicate that the KLD
forms a disulfide bond with PMEL C301 and therefore must be located near the PKD and
the RPT domains in the three-dimensional structure of p250 and p160. In this position,
the KLD could easily influence the structure of fibril-forming fragments by tethering the
region in such a way as to be incompatible with the cross-β sheet amyloid fold. The idea
that a disulfide bond can tether a protein in an amyloid-resistant conformation is not new
and was previously reported for the pathologic amyloid protein tau (150).
Alternatively, the KLD could function to promote an association between the RPT
domain and the fibril-forming NTR and PKD domains. Despite reports to the contrary
(92,93), the RPT is unlikely to be a core component of amyloid fibrils since PMEL fibrils
form much more rapidly in vivo than reported for the recombinant RPT domain in vitro
(91), PMEL fibrils in vivo are stable within melanosomes at neutral pH whereas those
produced from the RPT domain are stable only under acidic conditions, and the RPT
domain is heavily O-glycosylated in vivo. However, the RPT domain may stabilize fully
formed fibrils and/or facilitate the assembly of amyloid fibrils that have a particular
structure. Indeed, a PMEL variant lacking the RPT domain forms much more closely
packed fibrils (141) that could be harder to distinguish from unstructured aggregates by
electron microscopy.
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As previously discussed, the KLD could also catalyze a disulfide bond rearrangement
that converts PMEL from an amyloid-resistant to an amyloid-prone conformation. While
catalytic activity has never been reported for a KLD, the sensitivity of C301-KLD
disulfide bonds to reduction during cell lysis if not adequately protected by NEM
suggests that (1) the C301-KLD disulfide bond is solvent exposed and not buried deep
within the globular core of the protein and (2) the catalytic cysteine that facilitates the
reduction of this disulfide bond is either part of an abundant protein disulfide isomerase
present nearby or located within PMEL itself. Since the only known protein disulfide
isomerase of the endocytic pathway – GILT – is not expressed in melanocytes unless
treated with γ-interferon ((145,146) and M. Marks, unpublished data), this would require
the recruitment of an unknown protein disulfide isomerase. Thus, until additional protein
disulfide isomerases are identified within secretory and/or endocytic compartments, we
favor the interpretation that cysteine residues of the KLD can initiate disulfide bond
rearrangements within PMEL in an autocatalytic manner. Note, however, that we have no
structural information to suggest that one disulfide bond arrangement is more conducive
to amyloid formation than another and that the proposed catalytic activity of the KLD in
no way precludes it from also tethering or recruiting other PMEL domains.

Following up on p250
Functional amyloid proteins that are non-toxic in multiple cellular systems suggest the
presence of regulatory mechanisms that are (1) intrinsic to the proteins themselves and/or
(2) common to all cell types. We have proposed the formation of stable, non-toxic p250
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dimers as one intrinsic mechanism of regulation preventing premature PMEL fibril
formation early in the secretory pathway since p250 accumulation correlates with
impaired fibril formation in the C566S variant of PMEL. To more rigorously test our
model, however, we could tag PMEL with an FKBP domain, chemically induce
dimerization with the dimerizing agent FK1012 (169), and examine the effect this has on
PMEL fibril formation.
By chemically inducing dimerization, we might accumulate p250 PMEL dimers without
introducing mutations into the KLD domain of the protein. If, as we speculate, the
cysteine residues within the KLD can catalyze the resolution of p250, the inducible
dimerization domain should preserve the p250 dimer even after disulfide rearrangement
enabling us to determine whether dimerization alone is sufficient to inhibit PMEL
amyloid formation or whether the decrease in fibril formation observed in the C566S
PMEL variant results from a defective KLD. Alternatively or in conjunction with this
experiment, the F36M variant of FKBP could be used to make ligand-reversible PMEL
dimers. The advantage of this system is that the accumulated homodimers can be
completely dissociated within minutes by the addition of synthetic ligands (170).
Therefore, with this mutant we could test not only the effect of p250 accumulation on
amyloid fibril formation but also observe how the p250 dimers are processed once
released into the cell as monomeric protein. We could examine whether p250 dimers are
on-pathway intermediates of PMEL amyloid formation by monitoring p160, free Mα, and
Mα’ fragment formation. We could even analyze these cells by immunofluorescence
microscopy at various time points after the addition of FKBP ligand to see whether the
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released monomeric protein is targeted to melanosomes for incorporation into growing
amyloid fibrils or trafficked to lysosomes for degradation.

Subtleties of the C566S mutant
If our model was the only mechanism governing PMEL fibril formation, then all of
PMEL should be packaged into disulfide-bonded p250 dimers concomitant with ER exit.
These dimers would absolutely prevent unwanted fibril formation early in the secretory
pathway, and any disruption in dimer resolution would bring fibril assembly to a
standstill. In our experiments, however, fibril formation is not completely ablated in the
C566S variant of PMEL, suggesting that either not all PMEL exits the ER as p250 dimers
or that the dimers can be incorporated into fibrillar structures, albeit with decreased
efficiency. Since very little free P2 or free Mα is observed in HeLa cells expressing the
C566S mutant, it is unlikely that a significant portion of PMEL is exported from the ER
in a monomeric form. Therefore, we speculate that the single cysteine point mutation
C566S does not completely destroy the function of the KLD and that the C566S dimers
are converted to p160 at a reduced rate. Alternatively, the dimers themselves may
inefficiently polymerize into amyloid fibrils that resemble those formed by wild-type
PMEL, at least by thin section electron microscopy. To test for a p160 “leak,” cells
expressing the C566S variant of p250 could be treated with a BACE2 inhibitor to prevent
minute amounts of p160 from being rapidly assembled into amyloid fibrils. A metabolic
pulse-chase experiment would also be useful to determine whether the C566S mutant is
more slowly incorporated into detergent-insoluble fractions.
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Help from chaperone proteins
Many chaperone proteins were detected in our mass spectrometry analysis of affinitypurified PMEL including PDI family members, UGGT1, ERp44, and BiP. Given that
PMEL takes a long time to fold and exit the ER, it was not surprising to find that PMEL
associated with many components of the glycoprotein quality control system. We
considered the possibility that some of these chaperones continue to associate with PMEL
past ER exit and even investigated ERp57 (a PDI family member also known as PDIA3)
as a potential PMEL binding partner. The results showed that ERp57 associates with
immature PMEL isoforms but not mature Golgi-modified PMEL species, suggesting that
most of the chaperones we identified by mass spectrometry interact only with immature
forms of PMEL in the ER.
However, chaperones are important components of other functional amyloid systems
(46), and ER chaperones have been shown to traffic with aggregation-prone proteins
(171). Thus, it seems not improbable that a chaperone might traffic with mature PMEL to
ensure proper folding and prevent premature amyloid formation in secretory and
endocytic compartments. In our previous attempts to identify covalent binding partners of
PMEL by mass spectrometry, we used beads covalently conjugated to the αPMEL-C
antibody for affinity purification. Because this antibody does not distinguish between
mature and immature PMEL isoforms and because chaperones interacting with immature
ER folding intermediates likely outnumber those interacting with mature forms of PMEL,
it is hardly surprising that most of the peptides recovered in these experiments were
derived from chaperones that function exclusively within the ER. To enrich for
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noncovalent interactions involving mature PMEL isoforms, however, lysates could be
pre-cleared using beads covalently conjugated to αPMEL-I prior to affinity
chromatography using αPMEL-C. By pre-clearing the lysate over beads specific to ER
forms of PMEL, proteins that interact with immature PMEL can not only be removed
from the final sample but also serve as a useful point of comparison if eluted and
analyzed separately by mass spectrometry. Note that HMB45, the antibody specific for
mature forms of PMEL, is not suitable for immunoprecipitation or affinity purification.
Two regulators of PMEL fibril formation that should be enriched by the proposed
experiment are CD63 and apolipoprotein E (ApoE). Neither protein was detected in our
previous experiment, but both are involved in sorting mature PMEL to the ILVs of early
endosomes/stage I melanosomes and have been shown to co-immunoprecipate with
PMEL (78,79). The absence of these two proteins from our previous affinity
chromatography/mass spectrometry analysis, however, is not a flaw in that experiment
since we were specifically searching for covalent binding partners of PMEL and did not
analyze many regions of the gel outside p250 and p160.
A protein chaperone that might interact with both mature and immature forms of PMEL
is the 78 kDa glucose-regulated protein (GRP78, or BiP). BiP is an Hsp70 family
member that typically resides within the ER but has been observed outside the ER during
times of stress, especially on the cell surface of cancer cells (172). In addition, enormous
quantities of BiP were detected in a separate Coomassie-stained band in our affinity
chromatography/mass spectrometry experiment (data not shown) such that any
mechanism masking the ER retention motif of BiP would likely result in its co-secretion.
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PMEL in vitro
Some of the most tantalizing experiments await the purification of properly folded PMEL
isoforms. Thus far, this has been a huge challenge for the field as Mα isolated from E.
coli inclusion bodies retains very few (if any) of the regulatory mechanisms that govern
PMEL amyloid formation in vivo. At the same time, extraction of pre-amyloid PMEL
isoforms from mammalian tissue is not a viable strategy since (1) melanocytes comprise
only a minor fraction of skin cells and (2) melanosome biogenesis within the RPE occurs
primarily during prenatal development. Therefore, the best option currently available is to
purify the secreted form of PMEL (sPMEL) from the culture medium of MNT-1 human
melanoma cells.
Unlike recombinant Mα produced in bacteria, however, sPMEL is surprisingly resistant
to aggregation. Even after exposure to low pH, the reducing agent DTT, or the denaturant
urea, the vast majority of the protein remained in the soluble fraction following
ultracentrifugation at 100,000g (D. Harper, unpublished results). This suggests that
regulatory mechanisms governing the conversion of Mα from a non-amyloid to an
amyloid form are intact in sPMEL but that an additional factor might be necessary to
reconstitute fibril formation in vitro. Since fibril assembly typically occurs on ILVs, we
hypothesize that the missing component is a protein or lipid associated with ILVs. Until
that component can be identified, though, it may be useful to supply the reaction with
purified exosomes (which are, essentially, secreted ILVs).
If/when an in vitro system using correctly folded and processed PMEL is operational, we
will finally be able to perform kinetic and structural studies directly comparing PMEL
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amyloid with other pathologic amyloid proteins. At a minimum, the kinetics of wild-type
PMEL amyloid formation will be compared with that of Aβ and the C301S variant and
the final products examined by CD, FTIR, and X-ray fiber diffraction. But we could also
examine what types of stable oligomers and protofibrils are produced by the different
PMEL mutants, use synthetic protein modifications to monitor the conformational change
that occurs as PMEL converts from p250 to p160 to an amyloid form, or test the effect of
PMEL pre-formed fibrils (PFFs) on melanocytes versus neurons in culture to try and gain
additional insight into the question of whether PMEL amyloid is intrinsically less toxic
than that of pathological amyloid proteins – or whether differences in toxicity are entirely
a matter of context/regulation.

PMEL in vivo
While plenty of data support the amyloid structure of PMEL fibrils generated in vitro
using recombinant Mα produced in bacteria, the only evidence that PMEL forms amyloid
in vivo is that (1) melanosomes purified from bovine retinal pigment epithelia stain with
amyloid dyes and (2) detergent-insoluble clusters extracted from bovine melanosomes
stain with both Thioflavin S and PMEL. To perform additional structural studies,
however, we either need to purify µg-mg quantities of PMEL amyloid from bovine retina
or develop a way to generate sufficient material in cell culture. To start, melanosomes
might be isolated from wild-type or TYR-deficient melanocytes, and membrane depleted
using 1% Lubrol PX as was previously done for peptide hormones in pituitary secretory
granules (59). Even if the quantity of fibrils obtained is insufficient for structural studies,
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the material could be used to seed the formation of sPMEL fibrils that could then be
analyzed by CD, FTIR, and X-ray diffraction.

Concluding remarks
To date, mammalian functional amyloid proteins have been identified in the pituitary
(173), in the innate immune system (17), and in melanosomes (174). Of these, the
structure and function of PMEL in the melanosome is by far the best studied, yet very
little is known about how the protein converts from a non-amyloid to an amyloid form.
Here we described the formation of p250 PMEL dimers and proposed that resolution of
this species by the KLD contributes one layer of regulation to the timing of PMEL
amyloid formation. Future studies on the toxicity of wild-type PMEL and associated
variants, the biophysical characteristics of properly folded and processed PMEL
fragments, and the contribution of protein chaperones will continue to shed light on the
physiology and pathophysiology of amyloid in health and disease.
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APPENDIX A
Supplementary Figures
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Figure A1

Punctate HA-SLC45A2 structures do not co-localize with RAB38 or syntaxin-13.
Immortalized melan-uw1 melanocytes stably rescued with HA-SLC45A2 and transiently
transfected with RAB38-GFP (A) or syntaxin-13-GFP (B) were fixed, labeled with an
antibody against the HA tag and AF594-conjugated secondary antibody, and analyzed by
bright field (pseudocolored blue) and deconvolution immunofluorescence microscopy.
Shown are representative images of each channel separately and merged together. Insets
show 8.4x magnifications of the boxed regions. Scale bars represent 10 µm.
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Figure A2

Expression of HA-SLC45A2, HA-SLC45A2 Y268A, or HA-SLC35D3 protein in
melan-uw1 stable cell lines. Immortalized melan-uw1 melanocytes stably expressing
HA-SLC45A2 (lane 2), the Y268A variant of HA-SLC45A2 (lane 3), HA-SLC35D3
(lane 4), or the uninfected parental cell line (lane 1) were lysed in buffer containing 1%
Triton X-100. The detergent-soluble material was fractionated by SDS-PAGE,
transferred to a membrane, and immunoblotted with an antibody to the HA tag followed
by an antibody to γ-tubulin as a loading control. The migration of molecular weight
standards is indicated to the right. Arrows highlight bands corresponding to SLC45A2
and SLC35D3. Lane numbers are indicated across the bottom.

116

	
  

Figure A3

Immortalized melan-uw1 mouse melanocytes have more stage III and fewer stage
IV melanosomes. Electron micrographs of melan-ink (A, C) and melan-uw1 (B, D)
mouse melanocytes at low (A, B) and high magnifications (C, D). Scale bars represent
500 nm.
117

	
  

Figure A4

TYR and TYRP1 co-localize with faint pigment granules in melan-uw1 mouse
melanocytes. Immortalized melan-uw1 mouse melanocytes were fixed, labeled with
antibodies to TYR (PEP7), TYRP1 (TA99), PMEL (HMB45), and/or LAMP2 (GL2A7),
and analyzed by bright field and deconvolution immunofluorescence microscopy. Shown
are representative images of each channel separately and merged together. Insets show
8.25x magnifications of the boxed regions. Scale bars represent 10 µm.
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Figure A5

SLC45A2-deficient melan-uw1 melanocytes expressing OCA2 are highly pigmented.
Immortalized melan-uw1 mouse melanocytes transiently expressing OCA2-HA were
fixed, labeled with antibodies to TYRP1 (TA99) and the HA tag, and analyzed by bright
field and deconvolution immunofluorescence microscopy. Shown are representative
images of each channel separately and merged together. Insets show 8.25x
magnifications of the boxed regions. Scale bar represents 10 µm.
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Figure A6

Targeting vector used to generate conditional knock-in mice expressing wild-type or
TMinsWAP (DW) PMEL. Map of plasmid with left and right arms of homology for
insertion into the ROSA26 locus, the strong CAG promoter (CAG), a neomycin
resistance gene (neo) and a synthetic polyA transcriptional terminator (STOP) surrounded
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by loxP sites, the location of the wild-type or DW PMEL cDNA (PMEL), and an IRESGFP cassette.
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APPENDIX B
Materials and Methods

122

	
  

Antibodies and reagents
Unless otherwise specified, chemicals were obtained from Sigma-Aldrich (St. Louis,
MO) and tissue culture reagents from Life Technologies (Carlsbad, CA). Protease
inhibitors were purchased from Roche Diagnostics (Indianapolis, IN), gene amplification
primers from Integrated DNA Technologies (Coralville, IA), GoTaq DNA polymerase
from Promega Corp. (Madison, WI), and restriction enzymes and T4 DNA ligase from
New England Biolabs (Ipswich, MA). HMB45, a mouse monoclonal antibody to PMEL,
was purchased from Enzo Life Sciences (Catalog # ENZ-C34930; Farmingdale, NY).
Rabbit polyclonal antibodies PMEL-I, PMEL-N, PMEL-C, and PEP7 were affinity
purified as previously described (64,72,133,175). The mouse monoclonal antibody NKIbeteb was obtained from Lab Vision (Freemont, CA), and the anti-HA antibodies used
were 3F10 from Roche Diagnostics (Indianapolis, IN) and 16B12 from Covance
(Princeton, NJ). The antibody TA99 to TYRP1 was obtained from ATCC (Rockville,
MD), ab18528 to LAMP2A from abcam (Cambridge, MA), and GL2A7 to LAMP2 and
H4A3 to LAMP1 both from the Developmental Studies Hybridoma Bank (University of
Iowa, Iowa City, IA). Secondary antibodies conjugated to Alexa Fluor 488 or Alexa
Fluor 594 for immunofluorescence microscopy or to alkaline phosphatase for
immunoblotting were obtained from Jackson ImmunoResearch Laboratories (West
Grove, PA). Secondary antibodies conjugated to IRDye 800CW or IRDye 680LT for
immunoblotting were obtained from LI-COR Biotechnology (Lincoln, NE).

Cell culture and transfection conditions
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The highly pigmented MNT-1 human melanoma cell line was cultured as previously
described (129). The immortalized melanocyte cell lines melan-Ink4a and melan-uw1
were cultured in RPMI 1640 supplemented with 10% FBS (Atlanta Biologicals, Atlanta,
GA) and 200 nM 12-tetradecanoylphorbol 13-acetate (TPA) in 10% CO2 at 37˚C. The
culture medium of melan-uw1 melanocytes and derived stable transfectants was also
supplemented with 200 pM cholera toxin. Immortalized melanocyte cell lines were
transfected using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA). HeLa
cells were cultured in DMEM supplemented with 10% FBS in 5% CO2 at 37°C and
transfected with FuGENE 6 (Roche), FuGENE HD (Promega), GeneJuice (EMD
Millipore, Billerica, MA), jetPRIME (Polyplus-transfection SA, Illkirch, France), or
Xfect (Clontech Laboratories, Mountain View, CA) transfection reagents.

DNA constructs and cloning
The pCDM8.1 HA-SLC35D3 plasmid has been previously described (176). Wild-type
hPMEL (long form) and the cleavage site mutant ΔCS in the pCI vector (Promega) have
also been previously described (64,82) with cysteine mutants generated by site-directed
mutagenesis using two-step gene amplification (177). The human SLC45A2 cDNA in the
pCDNA4/TO-GFP vector was a gift from Dr. Elena Oancea (Brown University,
Providence, RI). This insert was PCR amplified with an N-terminal HA tag and inserted
into the pCI vector (Promega Corp., Madison, WI) to create HA-SLC45A2. The Y268A
variant of HA-SLC45A2 was generated by A. Lefkovith via site-directed mutagenesis
using two-step amplification (177). All inserts were verified by DNA sequencing.
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Sequences of primers used for gene amplification and for the production of all mutants
are available upon request.

Immunoblotting
Cells were harvested by centrifugation following release from plates with PBS, 5 mM
EDTA, then treated with PBS, 50 mM N-ethylmaleimide (NEM), and then lysed (~107
cells per mL) in lysis buffer [1% (w/v) Triton X-100, 150 mM sodium chloride, 0.02%
(w/v) sodium azide, 10 mM HEPES pH 7.4 supplemented with protease inhibitors and 50
mM NEM]. After centrifugation at 19,000g for 20 min, 1 volume of 6x SDS sample
buffer [0.4 M Tris pH 6.8, 12% (w/v) SDS, 34% glycerol, 0.02% (w/v) bromophenol
blue] with or without 11% β-mercaptoethanol was added to 5 volumes of detergentsoluble lysate. Samples were then heated at 60°C for 20 min, fractionated by SDS-PAGE
on Tris-glycine gels containing 7%, 10%, or 12% acrylamide, and electrophoretically
transferred to PVDF membranes. Membranes were blocked using blocking buffer [TBS
pH 7.4, 0.2% Tween-20, 5% (w/v) nonfat dry milk] or Odyssey Blocking Buffer (LICOR Biotechnology), incubated with primary antibodies diluted in blocking buffer, and
washed with TBST [TBS pH 7.4, 0.2% Tween-20]. In some experiments, membranes
were subsequently incubated with secondary antibodies conjugated to alkaline
phosphatase diluted in blocking buffer, washed with TBST, detected using enhanced
chemifluorescence (GE Healthcare Life Sciences, Piscataway, NJ), and analyzed using a
Molecular Dynamics Storm 860 Molecular Imager Phosphorimager (GE Healthcare Life
Sciences). In others, membranes were probed using secondary antibodies conjugated to
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IRDye-800CW or IRDye-680LT diluted in blocking buffer, washed with TBST, and
analyzed using an Odyssey Infrared Imaging System (LI-COR Biotechnology).
Quantification of bands was performed using the ImageJ Gel Analyzer tool
(http://fiji.sc/Fiji; National Institutes of Health) or Image Studio Lite (LI-COR).

Sucrose gradient sedimentation
Cells treated with PBS, 50 mM NEM were lysed in fractionation buffer [150 mM sodium
chloride, 0.02% (w/v) sodium azide, 100 mM Tris pH 7.4 supplemented with protease
inhibitor tablets, 50 mM NEM, and 20 mM iodoacetamide] containing 250 mM noctylglucoside. The lysate was clarified by centrifugation at 19,000g for 15 min, layered
on top of 5-20% sucrose gradients in 150 mM sodium chloride, 0.02% (w/v) sodium
azide, 25 mM n-octylglucoside, 100 mM Tris pH 8, and fractionated by sedimentation
velocity as described (178). Briefly, gradients were subjected to ultracentrifugation in a
Beckman L8-70M Ultracentrifuge (Beckman Coulter Inc., Brea, CA) for 38 h at 30,000
rpm in an SW-41 rotor. Fractions were collected from bottom to top using a peristaltic
pump, and aliquots of each fraction analyzed by non-reducing SDS-PAGE and
immunoblotting. Standard proteins (ovalbumin, rabbit IgG, bovine liver catalase, and/or
bovine thyroid thyroglobulin) were fractionated on parallel gradients; these fractions
were analyzed by reducing SDS-PAGE followed by staining with Coomassie Brilliant
Blue R-250.

Size exclusion chromatography
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Cells were lysed in fractionation buffer containing either 250 mM n-octylglucoside, 40
mM dodecyl-β-D-maltoside, or 4% (w/v) Triton X-100. After clarification at 19,000g for
15 min, detergent-soluble lysates were analyzed by size exclusion chromatography on an
ÄKTAFPLC system (GE Healthcare Life Sciences) using a Superose 6 10/300 GL
column (GE Healthcare Life Sciences) in running buffer [150 mM sodium chloride,
0.02% (w/v) sodium azide, 10 mM HEPES pH 7.4] containing a lower concentration of
the same detergent used for lysis – either 25 mM n-octylglucoside, 1 mM dodecyl-β-Dmaltoside, or 0.1% (w/v) Triton X-100. The column was eluted at a flow rate of 0.4 –
0.45 mL/min with a fraction volume of 300 or 600 µL. Aliquots of each fraction were
analyzed by non-reducing SDS-PAGE and immunoblotting. The elution volumes of
thyroglobulin (669 kDa), α2-macroglobulin (720 kDa), rabbit IgG (150 kDa), ovalbumin
(45 kDa), and/or cytochrome C (12 kDa) were also evaluated in separate runs with
fractions analyzed by SDS-PAGE followed by staining with Coomassie Brilliant Blue R250.

Metabolic labeling and immunoprecipitation
Metabolic labeling with 35S-methionine/cysteine and immunoprecipitation analyses were
conducted essentially as described (64). Briefly, cells were harvested by centrifugation
following digestion with trypsin-EDTA, washed, and cultured in suspension for 30 min in
methionine/cysteine-free DMEM containing 5% dialyzed FBS. Cells were then pelleted
and metabolically labeled in suspension in the same medium containing

35

S-Met/Cys

Express Mix (PerkinElmer, Waltham, MA) for 10-15 min (pulse/chase analyses) or 2 h
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(steady-state labeling for 2D-PAGE). For pulse/chase analyses, cells were pelleted again
and chased for the indicated periods of time in standard growth medium containing
excess methionine/cysteine as described (64). Cells were then lysed in lysis buffer and
clarified by centrifugation at 19,000g for 20 min. After first pre-clearing the lysates over
unconjugated protein A beads (Life Technologies) and then over protein A beads
conjugated to normal rabbit serum, normal mouse serum, or a mouse isotype control
antibody, the samples were subjected to immunoprecipitation using the antibodies
specified. The immunoprecipitated material was fractionated by SDS-PAGE, and the
resulting gels were dried and analyzed on a Phosphorimager as described above.

2-dimensional non-reducing/reducing SDS-PAGE
Triton X-100 lysates from cells metabolically labeled for 2 h were subject to
immunoprecipitation using the PMEL antibodies αPMEL-N, NKI-beteb, or αPMEL-C
after pre-clearing first with unconjugated protein A beads and then with protein A beads
conjugated to either normal rabbit serum or normal mouse serum as described above. The
immunoprecipitated material was then fractionated by SDS-PAGE in a 7%
polyacrylamide tube gel under non-reducing conditions. The tube gel was reduced by
incubation in 0.5% (w/v) DTT, 0.5% (w/v) SDS, 125 mM Tris pH 6.8 for 2 hours at room
temperature and then mounted and sealed (with 1% agarose) on top of a standard SDS
polyacrylamide gel. After fractionation by SDS-PAGE, the gels were dried and analyzed
on a Phosphorimager as detailed above.
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Immunoprecipitation/immunoblotting
HeLa cells expressing wild-type hPMEL or the C301S variant were released from plates
using PBS, 5 mM EDTA and harvested by centrifugation. The cells were treated with
PBS, 50 mM NEM on ice, pelleted, frozen, and subsequently lysed (~3 x 106 cells per
mL) in lysis buffer. Following clarification at 19,000g, lysates were pre-cleared over
unconjugated protein A beads prior to immunoprecipitation using NKI-beteb, αPMEL-C,
normal rabbit serum, or a mouse isotype control antibody pre-bound to protein A beads.
The beads were washed four times with wash buffer [0.1% (w/v) Triton X-100, 150 mM
sodium chloride, 0.02% (w/v) sodium azide, 10 mM HEPES pH 7.4] followed by one
wash with PBS. The immunoprecipitated material was then eluted by adding 2x SDS
sample buffer containing 3.6% β-mercaptoethanol and heating the samples for 20 min at
60°C. After fractionation by SDS-PAGE and transfer to PVDF membranes, immunoblots
were probed with αPMEL-C or HMB45 and analyzed using the Odyssey Imaging System
detailed above.

Proteomic analysis of p250 and p160
Affinity purification. Pellets of 2.6 – 7.8 x 108 NEM-treated MNT-1 cells were either
homogenized with a Dounce homogenizer and enriched for the total membrane fraction
as previously described (82) or lysed directly in lysis buffer and clarified by
centrifugation at 19,000g for 15 min. The detergent-soluble fraction was then loaded onto
3 columns in tandem containing Sepharose 4B (Sigma), rabbit IgG-conjugated agarose
(Sigma), and αPMEL-C-conjugated Sepharose (generated by combining 3 mL of 1
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mg/mL αPMEL-C with 3 mL of packed CNBr-activated Sepharose 4B from GE
Healthcare Life Sciences according to manufacturer’s instructions). The αPMEL-C
column was subsequently washed with 600 mL wash buffer and eluted using 0.63 µg/mL
PMEL-C peptide (CPIGENSPLLSGQQV, Peptide 2.0 Inc., Chantilly, VA). Eluate was
collected in 0.5 – 1 mL fractions and aliquots analyzed by immunoblotting for PMEL
content. Peak fractions were precipitated using a 5-fold volume of either methanol or
acetone at -20°C. The concentrated eluate was then fractionated on a 3-8% Tris-Acetate
protein gel (Life Technologies) and stained with Coomassie Brilliant Blue G-250.
In-gel digestion. Each sample was excised from the gel and cut into 1 mm cubes,
destained in a solution containing 50% methanol, 1.25% acetic acid, reduced with 5 mM
DTT (Thermo Fisher Scientific, Waltham, MA), and alkylated with 20 mM
iodoacetamide (Sigma). Gel pieces were then washed with 20 mM ammonium
bicarbonate (Sigma) and dehydrated with acetonitrile (Thermo Fisher Scientific). Trypsin
(Promega; 5 ng/mL in 20 mM ammonium bicarbonate) was added to the gel pieces, and
proteolysis was allowed to proceed overnight at 37ºC. Peptides were extracted with 0.3%
triflouroacetic acid (J.T.Baker of Avantor Performance Materials, Center Valley, PA),
followed by 50% acetonitrile. Extracts were combined and the volume was reduced by
vacuum centrifugation.
Mass spectrometry analysis. Tryptic digests were analyzed by LC-MS/MS on a hybrid
LTQ Orbitrap Elite mass spectrometer (Thermo Fisher Scientific) coupled with a nanoLC
Ultra (Eksigent Technologies Inc., Dublin, CA). Peptides were separated by reverse
phase (RP)-HPLC on a nanocapillary column, 75 µm x 15 cm Reprosil-pur 3 µm, 120 Å
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(Dr. Maisch, Ammerbuch, Germany) in a Nanoflex chip system (Eksigent). Mobile phase
A consisted of 1% methanol (Thermo Fisher Scientific), 0.1% formic acid (Thermo
Fisher Scientific) and mobile phase B of 1% methanol, 0.1% formic acid, 80%
acetonitrile. Peptides were eluted into the mass spectrometer at 300 nL/min with each
RP-LC run comprising a 90 min gradient from 10 to 25% B in 65 min, 25 to 40% B in 25
min. The mass spectrometer was set to repetitively scan m/z from 300 to 1800 (R =
240,000 for LTQ-Orbitrap Elite) followed by data-dependent MS/MS scans on the twenty
most abundant ions with a minimum signal of 1500, dynamic exclusion with a repeat
count of 1, repeat duration of 30 s, exclusion size of 500 and duration of 60 s, isolation
width of 2.0, normalized collision energy of 33, and waveform injection and dynamic
exclusion enabled. Fourier transform mass spectroscopy full scan automatic gain control
target value was 1E6, while MSn automatic gain control was 1E4. Fourier transform
mass spectroscopy full scan maximum fill time was 500 ms, while ion trap MSn fill time
was 50 ms; microscans were set at one. FT preview mode, charge state screening, and
monoisotopic precursor selection were all enabled with rejection of unassigned and 1+
charge states.
Protein Identification. MaxQuant/Andromeda version 1.5.2.8 was used to identify
proteins by searching against a human complete proteome sequence database downloaded
from Uniprot.org on 20140714. MaxQuant search parameters are detailed in the
parameters and summary tabs (see supplementary Microsoft Excel file), and the
identified protein groups and their estimated MS1 summed spectral intensities for each
gel slice are listed in the proteinGroups tab.
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Immunofluorescence microscopy
Cells grown on uncoated or Matrigel-coated coverslips were fixed with 2% formaldehyde
in PBS or HBSS, permeabilized and labeled with primary antibodies and fluorochromeconjugated secondary antibodies in PBS, 0.2% (w/v) saponin, 0.1% (w/v) BSA as
described previously (179), and analyzed on either a DM IRBE microscope (Leica
Microsystems, Wetzlar, Germany) equipped with a 63x or 100x Plan Apochromat
objective lens (1.4 NA; Leica), a Retiga Exi Fast 1394 digital camera (QImaging, Surrey,
Canada), and OpenLab software (Improvision, Lexington, MA) or a DMI 6000B
microscope (Leica Microsystems) equipped with the same objectives, an Orca Flash 4.0
V2 camera (Hamamatsu, Bridgewater, NJ), and Leica Application Suite X software
(Leica Microsystems). Images captured in sequential z-planes separated by 0.2 µm were
deconvolved and manipulated using the Volume Deconvolution module in OpenLab or
Gold's 3D deconvolution algorithm with 3-4 iterations in the Leica Application Suite.
Insets were magnified and further adjustments in brightness and contrast were performed
using Adobe Photoshop (Adobe Systems, Mountain View, CA).

Electron microscopy
For electron microscopy, melan-ink4a and melan-uw1 mouse melanocytes were grown in
10-cm dishes and fixed in situ, while HeLa cells transfected with pCI-PMEL wild-type,
C301S, or C566S with or without pEGFP-C1 (Clontech Laboratories) in a 9:1 ratio were
either fixed in situ, high-pressure frozen, or sorted for GFP expression prior to fixation in
132

	
  

suspension. For fixation in situ, cells were incubated in Karnovsky’s Fixative [4%
paraformaldehyde, 4 mM calcium chloride, 72 mM sodium cacodylate pH 7.4]
containing 0.5% glutaraldehyde for 1-2 h. This solution was then removed and replaced
with Karnovsky’s Fixative containing 2% glutaraldehyde and the cells fixed overnight at
room temperature. After the cells were scraped using a rubber policeman, the overnight
fixative was replaced with Karnovsky’s Fixative containing 0.5% glutaraldehyde and the
cells stored at 4°C. For high-pressure freezing, cells were released from plates using PBS,
5 mM EDTA, pelleted by centrifugation, and high-pressure frozen using an HPM 010
(ABRA Fluid, Widnow, Switzerland) by the Electron Microscopy Resource Laboratory
at the University of Pennsylvania. Sample dehydration by freeze substitution was
performed in a Leica AFSII (Leica Microsystems) over 72 h at -90°C in glass-distilled
acetone supplemented with 0.1% uranyl acetate and 2% OsO4. Cells were then embedded
in EPON resin at room temperature followed by polymerization for 48 h at 60°C. HeLa
cells sorted prior to fixation were co-transfected with pEGFP, released from plates using
PBS, 5 mM EDTA, and sorted for GFP expression on a Moflo Astrios EQ (Beckman
Coulter Inc.) by the CHOP Flow Cytometry Core. Similar to the cells sorted in situ, these
sorted cells were fixed for 1-2 hours in Karnovsky’s Fixative containing 0.5%
glutaraldehyde, overnight in Karnovsky’s Fixative containing 2% glutaraldehyde, and
stored in Karnovsky’s Fixative with 0.5% glutaraldehyde at 4°C. Both cells fixed in situ
and cells sorted prior to fixation were subsequently dehydrated and embedded in EMbed812 (Electron Microscopy Sciences, Fort Washington, PA) at the Electron Microscopy
Resource Laboratory. Ultrathin sections were cut on either a Reichert-Jung Ultracut E or
a Reichert Ultracut S microtome (now Leica Microsystems), placed on either uncoated
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copper mesh grids or Formvar-coated copper slot grids, and stained with 50% ethanol,
1% uranyl acetate, 1% lead citrate as previously described (180). The specimens were
then examined with a JEOL 1010 electron microscope fitted with a Hamamatsu C474295 digital camera (Hamamatsu, Bridgewater, NJ) and AMT Advantage image capture
software (Advanced Microscopy Techniques, Woburn, MA). For quantification of fibrilcontaining organelles, a combined total of at least 30 cells from the three independent
experiments were analyzed for each transfected cell type. The number of multivesicular
bodies that lacked fibrils and the number of multivesicular bodies that contained fibrils
(or fibrillar compartments lacking other internal structure) were quantified, and the
percentage of fibril-containing multivesicular bodies calculated for each cell. These data
were analyzed and plotted using Prism 6 (GraphPad Prism 6, La Jolla, CA), and
statistical analyses were performed using a two-tailed unpaired t-test.

Melanin quantification
Melanin from melan-uw1 stable cell lines was quantified by K. Haltaufderhyde as
previously described (181). Briefly, mouse melanocytes 50-90% confluent were lysed in
Triton X-100 and centrifuged at 14,000g for 30 min to obtain detergent-soluble and
detergent-insoluble fractions. The total protein present in the detergent-soluble fraction
was determined using a Bradford assay (Bio-Rad Laboratories, Hercules, CA). The
insoluble fraction was solubilized in 1 N NaOH, and total melanin content quantified by
comparing the optical density of each sample at 405 nm with that of synthetic melanin
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standards (Sigma). Average cellular melanin was then calculated as the ratio of total
melanin to total protein for each sample.
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